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Statistical Learning Methods for Personalized Medicine
Xin Qiu
The theme of this dissertation is to develop simple and interpretable individualized treatment rules
(ITRs) using statistical learning methods to assist personalized decision making in clinical prac-
tice. Considerable heterogeneity in treatment response is observed among individuals with mental
disorders. Administering an individualized treatment rule according to patient-specific character-
istics offers an opportunity to tailor treatment strategies to improve response. Black-box machine
learning methods for estimating ITRs may produce treatment rules that have optimal benefit but
lack transparency and interpretability. Barriers to implementing personalized treatments in clin-
ical psychiatry include a lack of evidence-based, clinically interpretable, individualized treatment
rules, a lack of diagnostic measure to evaluate candidate ITRs, a lack of power to detect treatment
modifiers from a single study, and a lack of reproducibility of treatment rules estimated from single
studies. This dissertation contains three parts to tackle these barriers: (1) methods to estimate
the best linear ITR with guaranteed performance among the class of linear rules; (2) a tree-based
method to improve the performance of a linear ITR fitted from the overall sample and identify
subgroups with a large benefit; and (3) an integrative learning combining information across trials
to provide an integrative ITR with improved efficiency and reproducibility.
In the first part of the dissertation, we propose a machine learning method to estimate optimal
linear individualized treatment rules for data collected from single stage randomized controlled
trials (RCTs). In clinical practice, an informative and practically useful treatment rule should be
simple and transparent. However, because simple rules are likely to be far from optimal, effective
methods to construct such rules must guarantee performance, in terms of yielding the best clinical
outcome (highest reward) among the class of simple rules under consideration. Furthermore, it
is important to evaluate the benefit of the derived rules on the whole sample and in pre-specified
subgroups (e.g., vulnerable patients). To achieve both goals, we propose a robust machine learn-
ing algorithm replacing zero-one loss with an authentic approximation loss (ramp loss) for value
maximization, referred to as the asymptotically best linear O-learning (ABLO), which estimates
a linear treatment rule that is guaranteed to achieve optimal reward among the class of all linear
rules. We then develop a diagnostic measure and inference procedure to evaluate the benefit of
the obtained rule and compare it with the rules estimated by other methods. We provide theo-
retical justification for the proposed method and its inference procedure, and we demonstrate via
simulations its superior performance when compared to existing methods. Lastly, we apply the
proposed method to the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial
on major depressive disorder (MDD) and show that the estimated optimal linear rule provides a
large benefit for mildly depressed and severely depressed patients but manifests a lack-of-fit for
moderately depressed patients.
The second part of the dissertation is motivated by the results of real data analysis in the first
part, where the global linear rule estimated by ABLO from the overall sample performs inadequately
on the subgroup of moderately depressed patients. Therefore, we aim to derive a simple and
interpretable piece-wise linear ITR to maintain certain optimality that leads to improved benefit in
subgroups of patients, as well as the overall sample. In this work, we propose a tree-based robust
learning method to estimate optimal piece-wise linear ITRs and identify subgroups of patients with
a large benefit. We achieve these goals by simultaneously identifying qualitative and quantitative
interactions through a tree model, referred to as the composite interaction tree (CITree). We
show that it has improved performance compared to existing methods on both overall sample and
subgroups via extensive simulation studies. Lastly, we fit CITree to Research Evaluating the Value
of Augmenting Medication with Psychotherapy (REVAMP) trial for treating major depressive
disorders, where we identified both qualitative and quantitative interactions and subgroups of
patients with a large benefit.
The third part deals with the difficulties in the low power of identifying ITRs and replicating
ITRs due to small sample sizes of single randomized controlled trials. In this work, a novel inte-
grative learning method is developed to synthesize evidence across trials and provide an integrative
ITR that improves efficiency and reproducibility. Our method does not require all studies to collect
a common set of variables and thus allows information to be combined from ITRs identified from
randomized controlled trials with heterogeneous sets of baseline covariates collected from different
domains with different resolution. Based on the research goal, the integrative learning can be used
to enhance a high-resolution ITR by borrowing information from coarsened ITRs or improve the
coarsened ITR from a high-resolution ITR. With a simple modification, the proposed integrative
learning can also be applied to improve the estimation of ITRs for studies with blockwise missing
feature variables. We conduct extensive simulation studies to show that our method has improved
performance compared to existing methods where only single-trial ITRs are used to learn personal-
ized treatment rules. Lastly, we apply the proposed method to RCTs of major depressive disorder
and other comorbid mental disorders. We found that by combining information from two studies,
the integrated ITR has a greater benefit and improved efficiency compared to single-trial rules or
universal non-personalized treatment rule.
Key Words: Personalized medicine; Machine learning; Treatment response heterogeneity; Indi-
vidualized treatment rules; Qualitative interaction; Quantitative interaction; Robust loss function;
Tree-based method; Integrative learning; Blockwise missing data
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Chapter 1
Introduction
1.1 Background and Overview
Heterogeneity in patient response to treatment is a long-recognized challenge in the clinical com-
munity. For example, in adults affected by major depression, only around 30% of patients achieve
remission with a single acute phase of treatment (Trivedi et al., 2006; Rush et al., 2004); the
remaining 70% of patients require augmentation of the current treatment or a switch to a new
treatment (Trivedi and Daly, 2008). Heterogeneity in treatment response also has been observed
among children with attention deficit and hyperactivity disorder (Pelham and Fabiano, 2008), and
autism spectrum disorders (Jones et al., 2010). Thus, a universal strategy that treats all patients
with the same treatment is inadequate, and individualized treatment strategies are required to im-
prove response in individual patients. In this regard, rapid advances in technologies for collecting
patient-level data have made it possible to tailor treatments to individual patients based on their
characteristics, thereby enabling the new paradigm of personalized medicine.
Personalized medicine aims to provide each patient with the right medicine, the right dose, and
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at the right time, in order to improve patient care and reduce potential side effects and health
care cost (Carini et al., 2014). As depicted in Figure 1.1, three types of patient’s covariates may
be considered to achieve this goal. The first class of covariates includes prognostic variables which
inform selecting subgroups of subjects at high risk for disease, irrespective of the treatment they
receive (Carini et al., 2014). The other two classes of covariates correspond to variables with
either quantitative or qualitative interaction with treatments, which are referred as predictive or
prescriptive variables, respectively. In particular, qualitative interaction refers to that the treatment
effect changes direction based on some function of covariates, which indicates that a treatment could
be superior in one subgroup but inferior in another subgroup. This type of interaction provides
important information on estimating a personalized treatment rule. Quantitative interaction refers
to that the treatment effects are in the same direction in the covariate space but differ in magnitude
in some subgroup. Predictive variables manifest quantitative interaction and define subgroups of
subjects who are likely to experience large treatment benefit, while prescriptive variables manifest
qualitative interaction and define the optimal treatment for a given individual. Both classes of
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variables can be used to guide the development of personalized medicine (Carini et al., 2014).
In the following of this dissertation, we develop several new statistical learning methods for
estimating simple and interpretable individualized treatment rules for single-stage randomized con-
trolled trials. The dissertation consists of three projects. We start by introducing background and
motivation of each project. In Chapter 2, we propose a machine learning method to estimate the
optimal linear individualized treatment rule and a diagnostic measure to assess the optimality of
candidate rules. In Chapter 3, we improve the performance of a linear ITR fitted from the over-
all sample using a tree-based model to identify both qualitative and quantitative interactions and
subgroups of subjects with a large benefit. In Chapter 4, we use integrative learning to synthesize
evidence across multiple trials to improve efficiency and reproducibility of the estimation of ITRs.
1.2 Introduction to Estimation and Evaluation of Linear Individ-
ualized Treatment Rules
Statistical methods have been proposed to estimate optimal individualized treatment rules (ITRs)
(Lavori and Dawson, 2004) using predictive and prescriptive clinical variables that manifest quanti-
tative and qualitative treatment interactions, respectively (Carini et al., 2014; Gunter et al., 2011).
Q-learning (Watkins, 1989; Qian and Murphy, 2011) and A-learning (Murphy, 2003; Blatt et al.,
2004) are proposed to identify the optimal ITR. Q-learning is a regression-based method, which esti-
mates an ITR by directly modeling the Q-function (“Q” stands for “quality of action”). A-learning
only requires posited models for contrast functions and uses a doubly robust estimating equation
to estimate the contrast functions. This makes A-learning more robust to model misspecification
than Q-learning and provides a consistent estimation of an ITR (Schulte et al., 2014). Other pro-
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posed approaches include semiparametric methods and machine learning methods (Moodie et al.,
2007; Zhang et al., 2012; Foster et al., 2011; Zhao et al., 2012; Chakraborty and Moodie, 2013).
For example, the virtual twins approach (Foster et al., 2011) uses tree-based estimators to identify
subgroups of patients who show larger than expected treatment effects. Zhang et al. (2012, 2013)
estimated the optimal ITR by directly maximizing the value function over a specified parametric
class of treatment rules through augmented inverse probability weighting. In contrast, Zhao et al.
(2012) proposed outcome weighted learning (O-learning), which utilizes weighted support vector
machine to directly maximize the value function (expected clinical outcome by following the ITR).
More recently, Huang and Fong (2014) proposed a robust machine learning method to select the
ITR that minimizes a total burden score due to disease and treatment for a binary clinical outcome.
Interactive Q-learning (Laber et al., 2014) models two ordinary mean-variance functions instead of
modeling the predicted future optimal outcomes. Fan et al. (2017) proposed a concordance function
for prescribing treatment, where a patient is more likely to be assigned to a treatment than another
patient if s/he has a greater benefit than the other patient.
In clinical practice, simple treatment rules such as linear rules, are preferred due to their trans-
parency and convenience for interpretation. However, when only linear rules are in consideration,
many existing methods including semiparametric models and some machine learning methods may
not yield a rule with optimal performance, because they focus on optimization of a surrogate ob-
jective function of treatment benefit. Using surrogate objective functions may only guarantee the
optimality when there is no restriction on the functional form of the treatment rules. For exam-
ple, with O-learning, the objective function is a weighted hinge-loss, which yields the optimal rule
among nonparametric rules, but may not be optimal when the candidate rules are restricted to the
linear form. Therefore, learning algorithms are desired to derive a treatment rule with guaranteed
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performance when constraints are placed on the class of candidate rules.
An additional consideration is the need to evaluate, through diagnostics, any approach for rule
estimation. However, less emphasis has been placed on the evaluation of the estimated ITR in the
context of personalized medicine. Residual plots were used to evaluate model fit for G-estimation
(Rich et al., 2010) and Q-learning (Ertefaie et al., 2016). In the recent work by Wallace et al.
(2016), a dynamic treatment regime (DTR) is estimated by G-estimation and double robustness
is exploited for model diagnosis. How to evaluate the optimality of an ITR in general remains an
open research question.
The purpose of this work is two-fold: we first develop a general approach to identify a linear ITR
with guaranteed performance; we then propose a diagnostic method to evaluate the performance
of any derived ITR including the proposed one. Our two-stage approach separates the estimation
of the ITR from its evaluation and the sample used in each stage. Specifically, in the first stage,
we propose ramp-loss-based (McAllester and Keshet, 2011; Huang and Fong, 2014) learning for the
estimation and we show that this approach guarantees the derived linear ITR to be asymptotically
optimal within the class of all linear rules. We refer our method as Asymptotically Best Linear O-
learning, ABLO. For the second stage, in practice, it is infeasible to expect that an ITR that benefits
each individual can be identified due to the unknown treatment mechanism and the likely omission
of some prescriptive variables. Thus, we propose a practical solution to calibrate the average ITR
effect in the population given the observed variables, or in pre-specified important subgroups (e.g.,
patients in the most severe state). Specifically, to obtain an ITR evaluation criterion, we define the
benefit of a candidate ITR as the average difference in the value function between those who follow
the ITR and those who do not. We then use the ITR benefit as a diagnostic measure to evaluate
its optimality. Our method exploits the fact that if an ITR is truly optimal for all individuals, then
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for any given patient subgroup, the average outcome for patients who are treated according to the
ITR should be greater than for those who are not treated according to the ITR. On the contrary,
if the average outcome of the ITR is worse for some patients who follow the ITR than for those
who do not, then the ITR is not optimal on this subgroup.
Compared to the existing literature, two main contributions of this work are to propose a benefit
function to calibrate an ITR, and a diagnostic procedure to evaluate optimality of a derived ITR,
while most of the existing work focuses on the estimation of ITR/DTR. A third contribution is
to prove asymptotic properties of ITR estimated under the ramp loss (Huang and Fong, 2014).
Asymptotic results in the existing literature (e.g., Zhao et al. (2012)) are obtained for the hinge
loss. Due to these theoretical results, we can provide valid statistical inference procedure for testing
optimality of an ITR using asymptotic normality.
In Chapter 2, we show that ABLO consistently estimates the ITR benefit for a class of candi-
date rules regardless of two potential pitfalls: 1) the consistency of benefit estimator is maintained
even though the functional form of the rule is misspecified; 2) the rule does not include all pre-
scriptive/tailoring variables and thus the true global optimal rule is not in the specified class. We
further derive the asymptotic distribution for the proposed diagnostic measure. We conduct simu-
lation studies to demonstrate finite sample performance and show advantages over existing machine
learning methods. Lastly, we apply the method to the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) trial on major depressive disorder (MDD), where substantial treatment re-
sponse heterogeneity has been documented (Trivedi et al., 2006; Huynh and McIntyre, 2008). Our
analyses estimate an optimal linear ITR, and we demonstrate a large benefit in mildly depressed
and severely depressed patients but a lack-of-fit among moderately depressed patients.
CHAPTER 1. INTRODUCTION 7
1.3 Introduction to Composite Interaction Tree for Learning Op-
timal Individualized Treatment Rules and Subgroups
Due to their simplicity and interpretability, decision trees are often constructed to assist person-
alized medical decision making. Two types of interactions are useful for personalizing treatments:
qualitative interactions inform the selection of optimal treatment from several competing choices;
quantitative interactions inform the identification of subgroups with a substantially greater or
smaller response than the overall sample. Methodologies are proposed to estimate an optimal ITR
by hunting for qualitative interactions between covariates and treatments on the outcome (Carini
et al., 2014; Gunter et al., 2011; Dusseldorp and Van Mechelen, 2014; Laber and Zhao, 2015).
Specifically, Qualitative interaction tree (QUINT, Dusseldorp and Van Mechelen, 2014) partitions
patients into terminal nodes where the average effect of one treatment for patients in the nodes is
superior or two treatments are similar. Unlike the usual classification trees or regression trees where
class labels are known, in tree-based methods for estimating optimal ITRs the optimal treatment
(class label) for an individual is unknown. In this regard, Minimum Impurity Decision Assignments
decision trees (MIDAs, Laber and Zhao, 2015) focused on the estimation of a tree-structured ITR
that maximizes a value function and splits the parent nodes where the value function will be most
dramatically improved. Fu et al. (2016) proposed to maximize the value function by exhaustive
search; their approach was shown to be more stable due to using residuals of a regression model
to remove main effects of covariates on the outcome when learning a tree (Liu et al., 2014). In a
recent work by Zhu et al. (2017), outcome weighted learning (Zhao et al., 2012) and reinforcement
learning tree (Zhu et al., 2015) were combined to construct a tree-based model to perform treatment
selection. The algorithm uses greedy search where at each step, a weighted classification score is
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used to evaluate the potential contribution of each variable.
Another group of methods is proposed to identify treatment response heterogeneity through
estimating quantitative interactions. In this case, the optimal treatment may be the same for
a subgroup of patients but they manifest a greater benefit than the overall sample. Subgroup
Identification based on Differential Effect Search (SIDES, Lipkovich et al., 2011) searches within
certain regions of the covariate spaces and identifies multiple subgroups with enhanced treatment
effects. At each step, SIDES partitions a parent node into two child nodes for each covariate in a
pre-specified set and retains the child node with a larger treatment effect. Virtual twins (Foster
et al., 2011) finds a subgroup of patients who will have larger treatment effect using tree-based
estimators. Interaction trees (ITs, Su et al., 2009) can identify both qualitative and quantitative
interaction, but cannot distinguish strong quantitative interaction from qualitative interaction.
Some of the above existing tree-based approaches (e.g., QUINT, IT) examine qualitative inter-
action by exploring each candidate feature variable in turn. However, due to biological and clinical
heterogeneity among patients, a single variable is unlikely to successfully guide treatment choice
in individual patients; information carried by a single variable is limited, and a large number of
variables each with small effects may play a role. Thus, tree-based approaches that partitions by
individual variables may have reduced performance. For instance, in a randomized trial treating
major depressive disorder (STAR*D, Rush et al., 2004), QUINT did not return any individual
variable that can distinguish the best treatment to reduce depressive symptoms. In contrast, using
the same study data, machine learning and regression-based approaches (Chakraborty and Moodie,
2013; Qiu et al., 2017) identified ITRs as linear combinations of feature variables that manifest a
qualitative interaction to differentiate optimal treatments for individual patients. However, a lin-
ear ITR fitted from the overall sample using these methods may not be optimal on some patient
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subgroups (due to the misspecification of linear rules), and thus do not identify subgroups with
large ITR benefits.
Recognizing that estimating an ITR and identifying subgroups with large ITR benefits are
two important goals, we propose a novel composite interaction tree, referred to as CITree, to
simultaneously estimate qualitative and quantitative interactions. CITree contains two types of
splits: a qualitative-interaction split by fitting asymptotically best linear rule (ABLO) at each
stage; and a quantitative-interaction split based on a heterogeneity of ITR benefit (HTB) test.
Specifically, in the qualitative split CITree estimates an interpretable, simple decision tree that
guarantees enhanced performance on subgroups of patients by improving the value function fitted
from the overall sample. Patients are partitioned into homogeneous subgroups of similar optimal
ITR (reduce optimal treatment rule heterogeneity). In the quantitative split, CITree partitions
patients into homogeneous subgroups of ITR benefit such that the within-group optimal ITR effect
is similar while the between-group difference is large (reduce ITR benefit heterogeneity).
CITree leverages a diagnostic measure of the goodness-of-fit of a decision rule and a measure
of the ITR benefit (i.e., the difference in the mean response for patients who follow the ITR and
those who do not). It has been shown in Chapter 2 that if an optimal ITR genuinely maximizes
the clinical response in each individual patient, then the ITR will have a positive effect within any
arbitrarily defined subgroup of patients. Thus, by an HTB test, it is feasible to determine for which
patients a linear (and potentially misspecified) ITR leads to a significantly lower than average (and
potentially negative) benefit; thus the treatment is more likely to be non-optimal for these patients.
To remedy this lack-of-fit of linear rules, as patients travel down the CITree, non-optimal ITRs with
a poor benefit at top nodes are rectified in subgroups and patients organize into nodes of a high or
low ITR benefit. By recursively detecting subgroups with a low benefit (quantitative splits) and
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re-fit ITR within the subgroups (qualitative split), CITree will improve the overall value function
and increase the subgroup benefit.
In Chapter 3 of this dissertation, we further introduce the rationale and algorithm of CITree.
We show that CITree can successfully reduce the benefit heterogeneity and rule heterogeneity. We
then perform extensive simulation studies to show improvement as compared to existing machine
learning methods (e.g., IT, QUINT). Lastly, we fit a CITree using the Research Evaluating the
Value of Augmenting Medication with Psychotherapy (REVAMP) trial data for treating major
depressive disorder (MDD), where substantial treatment response heterogeneity was documented
in the literature (Shankman et al., 2013).
1.4 Introduction to Integrative Learning to Synthesize Individu-
alized Treatment Rules Across Multiple Trials
Several challenges hamper the success of developing and implementing personalized treatment de-
cisions in clinics. First, recent machine learning methods (Zhao et al., 2012, 2015) for discovering
individualized treatment rules (ITRs) lack interpretability, and thus, they are difficult to under-
stand by clinicians and translate into clinical practice. Second, most randomized controlled trials
(RCTs) are powered to detect average treatment effects instead of subgroup effects, let alone op-
timal individualized treatment decisions. Thus, subgroup or ITR findings are difficult to replicate
due to small sample sizes. Third, the target population for the application of ITRs can be different
from the patient sample used in estimating the ITR due to time, geographic, or other differences
(Justice et al., 1999). When learning an ITR based on a single study, the research aim is to estimate
an ITR that performs best on the current study, which may not be able to transport or generalize
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to a future sample due to sample difference between studies and the study-specific noise variables.
A cost-effective method to remedy the small sample size problem and improve the reproducibility
and transportability is to pool and analyze data from multiple RCTs, which includes meta-analysis
(Haidich, 2010) and integrative analysis approaches (Ma et al., 2011). Meta-analysis uses a weighted
average to compute a pooled estimate of an average overall treatment effect from individual studies
(Cipriani et al., 2018; Jakobsen et al., 2017). Subgroup analyses are exploratory in nature, and well-
designed studies testing the same subgroup effect is scarce in the literature. Therefore, conducting
subgroup meta-analysis across multiple trials is difficult. For example, we performed a systematic
review of subgroup analysis of RCTs of major depressive disorder (MDD). There were 211 studies
that met our inclusion criteria, but with only one consensus predictive variable (i.e., baseline severity
of depression), suggesting that the literature is incomplete and inconclusive given the substantial
observed heterogeneity in treatment effects (HTE). On the other hand, we didn’t find any research
performing meta-analysis for ITRs because there is no straightforward method to average ITRs
from individual studies given that an ITR is usually the sign of a decision function. Integrative
analysis approaches pool raw data from multiple studies and analyze the pooled data as if it is
from a single trial. Integrative analysis can be more effective than meta-analysis (Ma et al., 2011),
and has been used in detecting genetic risk factors from multiple cancer studies or cancer subtypes.
However, it requires that multiple studies share the same biological ground and the same candidate
feature variables should be collected from all the studies.
In practice, due to different study designs and hypotheses, RCTs often collect different sets of
baseline covariates or feature variables. When new evidence from neuroscience research emerges,
new hypotheses are proposed regarding various biomarkers as predictive/prescriptive variables for
pharmacotherapy of MDD (Trivedi et al., 2016). Thus, biomarkers are one of the foci of data collec-
CHAPTER 1. INTRODUCTION 12
tion, in addition to clinical and neuropsychiatric measures (EMBARC, Trivedi et al. (2016)), while
in prior studies (e.g, STAR*D (Rush et al., 2004), CO-MED (Rush et al., 2011), HEAL (Shear
et al., 2016), REVAMP (Kocsis et al., 2009), Nefazodone-CBASP (Keller et al., 2000), Bulimia
(Sysko et al., 2010)), only comprehensive clinical variables are available. In particular, EMBARC
trial collects comprehensive baseline measures including clinical measures, depression and anxiety
measures, behavioral phenotyping (BP), functional magnetic resonance imaging (fMRI), electroen-
cephalogram (EEG), and diffusion tensor imaging (DTI). In addition to clinical measures, depres-
sion and anxiety measures, STAR*D and Co-Med also include information for measuring quality
of life, work and social adjustment, while HEAL consists of additional variables to measure grief
symptoms and treatment expectancy.
Non-uniform, heterogeneous feature collection poses challenges for the integration of ITRs or
meta-analysis across RCTs. Combining data directly and performing a single analysis is often
inefficient or inappropriate. For example, one may consider to use all subjects with common feature
variables across trials and treat it as a single study, which may lose information of important feature
variables. On the other hand, to include as many feature variables as possible, one may end up
with a small number of subjects in the analysis, which may lead to a biased sample to represent
the entire population.
Because available feature variables in each trial differ, treatment rules estimated from each trial
will include different “resolutions” of the patient-specific characteristics (i.e., ITRs from EMBARC
may depend on both clinical variables and brain imaging biomarkers, whereas ITRs from STAR*D
depend only on clinical variables). The fitted ITRs may yield opposite treatment recommendations
for the same patient based on different feature variables included. A conundrum is that although
ITRs learned with a rich set of feature variables and finer resolution may prescribe more specific
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treatment for an individual patient, these ITRs can be less reliable due to an increased number of
tailoring variables. Conversely, coarsened ITRs learned using fewer variables are more robust and
practical in resource-limited clinical settings (e.g., when collecting data on expensive biomarkers
is prohibitive). However, these ITRs may not lead to a truly optimal personalized treatment.
Therefore, integration and reconciliation of the ITRs learned on heterogeneous scales are important.
We will propose novel analytic solutions to the above challenges. Our proposed method is related
to Multi-Task Learning (MTL) and Multi-Objective Reinforcement Learning (MORL). One type of
MTL (Ruder, 2017) is to optimize one loss function with related auxiliary tasks to improve the main
task. MORL (Liu et al., 2015) aims to optimize multiple objectives by summarizing them into one
single objective. When multiple studies collecting features with different resolutions are available,
depending on the main study of interest and information available in the future target population
of applying the estimated ITR, other studies can be included as auxiliary data sets to improve
the efficiency and reproducibility of the ITR comparing to using the main study data set alone.
When learning a high-resolution ITR is of interest, the auxiliary data sets often collect a subset
of feature variables which can provide low-resolution ITRs. If a simple and easy to interpret low-
resolution ITR is of interest, auxiliary data sets with high-resolution ITRs can still assist improving
the coarsened ITR based on the low-resolution information.
To improve efficiency and reproducibility of ITRs from both directions, we propose a novel in-
tegrative learning to synthesize evidence across trials and provide an integrative ITR. Our method
does not require all studies to collect common sets of variables. Thus, the integrative learning allows
evidence to be combined from ITRs identified in recent RCTs that collected emerging biomarkers
(e.g., neuroimaging measures) with earlier RCTs that focused on clinical and psychosocial markers.
The proposed method will summarize information across different trials by a regularized value func-
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tion and use a data-driven method to determine how much evidence each study contributes to the
integrative ITR. Optimization of the regularized value function can be easily solved using existing
outcome-weighted learning methods (Zhao et al., 2012; Qiu et al., 2017) with an augmentation term
related to the clinical outcome.
In Chapter 4 of this dissertation, we first introduce the rationale and algorithm of the proposed
integrative machine learning method for learning both high-resolution ITRs and coarsened ITRs.
We then extend the proposed method to studies collecting blockwise feature domains. We derive
the underlying Bayesian rules for the proposed method. We show that the proposed method
can successfully improve the efficiency and reproducibility of the estimated ITRs compared to
existing machine learning methods for single studies (e.g., ABLO) via extensive simulation studies.
Lastly, we fit ITRs using the proposed integrative learning method on Establishing Moderators
and Biosignatures of Antidepressant Response in clinical Care (EMBARC) trial for treating major
depressive disorder.
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Chapter 2
Estimation and Evaluation of Linear
Individualized Treatment Rules to
Guarantee Performance
2.1 Overview
In this chapter, we propose a machine learning method, asymptotically best linear O-learning
(ABLO) to estimate the optimal linear ITR. We also propose a diagnostic measure to evaluate
candidate ITRs. In Section 2.2, we propose the statistical method of ABLO and several tests for
goodness-of-fit. In Section 2.3, we show the asymptotic properties. In Section 2.4, we conduct
simulation studies to investigate the performance of the proposed method. In Section 2.5, we apply
the method to a study of patients with major depressive disorder, the STAR*D data. Finally, we
summarize our findings and discuss possible extensions in Section 2.6.
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2.2 Methodologies
We start by introducing some notations for single-stage randomized clinical trials. Let R denote
a continuous variable measuring clinical response after treatment (e.g., reduction of depressive
symptoms). Without loss of generality, assume a large value of R is desirable. Let X denote a
vector of subject-specific baseline feature variables, and let A = 1 or A = −1 denote two alternative
treatments being compared. Assume that we observe (Ai,Xi, Ri) for the ith subject in a two-arm
randomized trial with randomization probability P (Ai = a|Xi = x) = pi(a|x), for i = 1, ..., n.
An ITR, denoted as D(X), is a binary decision function that mapsX into the treatment domain
A = {−1, 1}. Let PD denote the distribution of (A,X, R) in which D is used to assign treatments.
The value function of D satisfies













where P is the distribution of (A,X, R) and PD is the distribution under A = D(X). In most
applications, D(X) is determined by the sign of a function, f(X), which is referred to as the ITR
decision function. That is, D(X) = sign(f(X)). In general settings, f ∈ F can take any form, either
a parametric function or a non-parametric function. To quantify the benefit of an ITR, a measure
related to the value function is a natural choice. The mean difference is widely used to compare
the average effect of two treatments. Analogously, we define the benefit function corresponding to
an ITR as the difference in the value function between two complementary strategies: one that
assigns treatments according to D(X) and the other assigns according to the complementary rule










CHAPTER 2. ESTIMATION AND EVALUATION OF LINEAR INDIVIDUALIZED
TREATMENT RULES TO GUARANTEE PERFORMANCE 17
2.2.1 Estimating Optimal Linear Treatment Rule
To obtain a practically useful and transparent ITR, we consider a class of linear ITR decision
functions, denoted by L, and estimate the optimal linear function f∗L ∈ L, that maximizes the
value function (2.1) among this class. To this end, following the original idea of Liu et al. (2014),








where r(X) is any function of X, taken as an approximation to the conditional mean of R given













for f ∈ L, where Wi = Ri − r̂(Xi), Zi = sign(Wi), and r̂(X) is obtained from a working model by
regressing Ri on Xi (Liu et al., 2014).
The above optimization with zero-one loss is a non-deterministic polynomial-time hard (NP-
hard) problem (Natarajan, 1995). To avoid this computational challenge, the zero-one loss was
replaced by some convex surrogate loss in existing methods, for instance, the squared loss or hinge
loss. Let f∗ denote the global optimal decision function corresponding to the optimal treatment
rule among any decision functions. That is, f∗(X) = E(R|A = 1,X) − E(R|A = −1,X). When
L consists of linear decision functions that are far from the global optimal rule such that f∗ 6∈ L,
estimating optimal linear rule by minimizing the surrogate loss (e.g., hinge loss or squared loss) no
longer guarantees that the induced value or benefit is maximized among the linear class.
In order to obtain the best linear ITR with guaranteed performance, we propose to use an
authentic approximation loss that will converge to zero-one loss, referred to as the ramp loss
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(McAllester and Keshet, 2011; Huang and Fong, 2014), for value maximization. The ramp loss, as
plotted in Figure 2.1, has been used in the machine learning literature to provide a tight bound on
the misclassification rate (McAllester and Keshet, 2011; Collobert et al., 2006). Mathematically,
this function can be expressed as












where s is a tuning parameter to be chosen in a data-adaptive fashion. Clearly, when s converges
to zero, the ramp loss function converges to the zero-one loss; thus, we expect that the estimated
rule from this loss function should approximately maximize the value function among class L.
Figure 2.1: Different approximation functions of the zero-one loss

















Specifically, with the ramp loss (2.3), we propose to estimate the optimal linear ITR decision
function, f∗L(X), by minimizing the penalized weighted sum of ramp loss of a linear decision function
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where C is the cost parameter, which is a tuning parameter that determines the penalty placed
on misclassifying a subject’s optimal treatment. Because the ramp loss is not convex, we solve the
optimization by the difference of convex functions algorithm (DCA) (An et al., 1996). First, we
express hs(u) as the difference of two convex functions. That is,









where function (x)+ denotes the positive part of x. Let ηi denote ZiAif(Xi). Then the penalized






2 ||β||2, and the minimization
in (2.4) can be carried out in three steps:
• Step 1: Start with an initial value of β, i.e. β0, which can be derived from the linear rule
estimated by the O-learning with hinge loss. Then, the initial value of η can be calculated
and we denote it as η0.
• Step 2: Solve
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• Step 3: Compute η0 and update it in step 2 until the change in L is less than a pre-specified
threshold.
In order to solve the optimization problem in Step 2, we introduce slack variables ξi to replace












, and ξi ≥ 0.
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Let γ be a vector with i-element γi =
|Wi|h′2,s(η0i )
pi(Ai|Xi) . Notice that ηi = AiZi(β0 + X
T
i β), and take































pi(Ai|Xi)C − αi − τi. (2.8)






















































































where Q is a square matrix where Qi,j =< AiZiXi, AjZjXj >.






(1− 2CQγ/s)T α, (2.9)




AiZiαi/s = 0. Thus, the optimization
problem can be solved via quadratic programming. After obtaining αi, the original coefficient can
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Xi. Based on the KarushKuhnTucker (KKT) condition
ξi(C|Wi|/pi(Ai|Xi) − αi) = 0, when 0 < αi < C|Wi|/pi(Ai|Xi), we have ξi = 0 and AiZi(β̂0 +




Therefore, we obtain the optimal linear ITR as
f̂∗L(X) = β̂0 +X
T β̂,
and denote the optimal ITR as sign(f̂∗L(X)). In Section 2.3, we show that f̂
∗
L converges to the
true best linear rule, f∗L, asymptotically, at a slower rate than the usual root-n rate. We refer the
proposed estimation procedure as Asymptotically Best Linear O-learning, ABLO. We also prove
the asymptotic normality of β̂ and the estimated benefit function, which provides justification of
the inference procedures proposed in Section 2.2.2 and 2.2.3.
2.2.2 Performance Diagnostics for the Estimated ITR
ABLO guarantees that the optimal value among the class L is achieved asymptotically. Never-
theless, the optimal linear rule f∗L(X) may still be far from the global optimal, f
∗, such that for
some important subgroups, f∗L(X) may be non-optimal or even worse than the complementary
treatment rule. Therefore, an empirical measure must be constructed to evaluate the performance
of an estimated ITR.
To develop a practically feasible diagnostic method for any estimated ITR, given by sign(f̂(X)),
we note that if f̂(X) is truly optimal among any decision functions in F , i.e., f̂(X) has the same
sign as f∗(X), then for any subgroup defined by X ∈ C for a given set C (e.g., C can represent the
subset of mildly depressed patients with QIDs score less than 11) in the domain of X, the value
function for those subjects whose treatments are the same as sign(f̂(X)) should always be larger
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than or equal to the value function for those subjects with the same X ∈ C, but whose treatments
















= I(f∗(X) > 0)E(R|A = 1,X) + I(f∗(X) ≤ 0)E(R|A = −1,X)
−I(f∗(X) > 0)E(R|A = −1,X)− I(f∗(X) ≤ 0)E(R|A = 1,X)
= |f∗(X)|
≥ 0.
















should be non-negative. On the other hand, if δC(f̂) ≥ 0 holds for any subset C, then the above
derivation also indicates that f̂(X) must have the same sign as f∗(X), i.e., f̂(X) is the optimal
treatment rule for subjects in C.
These observations suggest a diagnostic measure δC(f̂) for any subgroup C. Specifically, we





Xi ∈ C, Ai = sign(f̂(Xi))
}
Ri/pi(Ai,Xi)∑n





Xi ∈ C, Ai 6= sign(f̂(Xi))
}
Ri/pi(Ai,Xi)∑n
i=1 I(Xi ∈ C)
. (2.10)
Because δ̂C(f̂) approximates δC(f̂), the measure δ̂C(f̂) is expected to be positive with a high prob-
ability if f̂(X) is close to the global true optimal. Furthermore, the evidence that δ̂C(f̂) is positive
for a rich class of subsets C will support the approximate optimality of f̂ in the class. However,
because it is infeasible to exhaust all subgroups, we suggest a class of pre-specified subgroups
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. A positive value of ∆̂(f̂) implies approximate optimality of f̂
when m is large enough. In practice, we consider Ck to be pre-specified groups or the sets de-
termined by the tertiles of each component of X, for example, the jth component of X below
its first tertile, between the first and the second tertiles, or above the second tertile. Moreover,
using the proposed diagnostic measure, by examining the subsets C (or tertiles defined by variables)
with negative or close to zero values of δ̂C(f̂), we can identify subgroups or components of X for
which the estimated rule f̂ may not be sufficiently optimal. Thus, we can further improve the rule
estimation in this subgroup to obtain an improved ITR.
If the same data are used for estimating the optimal ITR and performing diagnostics, the latter
may not be an honest measure of performance (Athey and Imbens, 2016). Thus, we suggest the
following sample-splitting scheme. Divide the data into K folds, and denote f̂ (−k) as the optimal
ITR obtained using data without the kth-fold. Next, benefit of each f̂ (−k) is calibrated on the
kth-fold data using the diagnostic measure and then averaged. Let nk denote the sample size of
the kth-fold, and let Ik index subjects in this fold. The honest diagnostic measure for subgroup C




















Ai = −sign(f̂ (−k)(Xi))
}]
Ri/pi(Ai|Xi).
We will implement this scheme in subsequent analysis.
2.2.3 Inference Using the Diagnostic Measure
The proposed diagnostic measure, δ̂C(f̂), can be used to compare different ITRs and non-personalized
rules, make comparisons within certain subgroups, and assess heterogeneity of ITR benefit (HTB)
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across subgroups. Hypotheses of interest may include:




L)− δ0 = 0 v.s. H1 : δ(f∗L)− δ0 > 0,
where δ0 is the average treatment effect of a non-personalized rule (difference in the mean
response between treatment groups). For this purpose, we can construct the test statistic
based on δ̂C(f̂) − δ0, where f̂ is obtained from any method, and C is the whole population.
We reject the null hypothesis at a significance level of α if the (1−α)-confidence interval with
∞ as the upper bound for δ̂C(f̂)− δ0 does not contain 0.




L)− δ0k = 0 v.s. H1 : δCk(f∗L)− δ0k > 0,
where δ0k is the average treatment effect in the subgroup. The same test statistic as the
previous one can be used but with C = Ck.
• Test the HTB across subgroups {C1, · · · , CK}, i.e.,
H0 : δCk(f
∗
L)− δCK (f∗L) = 0, k = 1, · · · ,K − 1.






C = (δ̂C1(f̂)− δ̂CK (f̂), · · · , δ̂CK−1(f̂)− δ̂CK (f̂)). It can be shown that T asymptotically
follows χ2K−1 under H0, so we reject H0 when T is larger than the (1− α)-quantile of χ2K−1.
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• Test the non-optimality of the best linear rule f∗L in a subgroup C by evaluating
H0 : δC(f∗L) ≥ 0 v.s. H1 : δC(f∗L) < 0.
For this purpose, we can directly use δ̂C(f̂) and reject the null hypothesis if the confidence
interval with lower bound of −∞ does not contain zero.
The asymptotic properties of β̂ and δ̂C(f̂) are required to perform inference above. Based on the
theoretical properties (asymptotic normality) given in Section 2.3, we propose a bootstrap method







i ), where i = 1, 2, · · · , n, and re-estimate residuals as W˜ (b)i in (2.5). Next, we re-fit
treatment rule f˜ (b) and obtain δ˜
(b)
C (f˜
(b)). The 95% confidence interval for δ̂C(f̂) is constructed from
the empirical quantiles of δ˜
(b)
C (f˜
(b)), b = 1, 2, · · · , B.
2.3 Asymptotic Properties
Let X denote a vector with one as the first component and the remaining components as feature
variables. To emphasize that the tuning parameter s of ramp loss may depend on the sample size
to establish asymptotic properties, we denote it by sn in this section. We assume
(a) The true optimal linear function, f∗L(x) = x
Tβ∗, is the unique minimizer of E {RI(Af(X) < 0)}
for f(x) = xTβ where ‖β‖ = 1. Furthermore, there exists a positive constant δ0 such that
P (|XTβ∗| > δ0) = 1.
(b) The joint densities of (R,X) given A = 1 and −1 are twice-continuously differentiable.
(c) There exits a function r(x) such that {r̂(x)− r(x)} = o((nsn)−1/2) uniformly in x, where r̂(x)
is estimated from a working regression model of R on X.
(d) (nCn)
−1 → 0, nsn →∞, ns3n → 0, and (nsn)1/2(nCn)−1 → 0.
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(e) There exits a unique minimizer, denoted by βn, that minimizes
E
[|R− r(X)|hs {A sign(R− r(X))XTβ} /pi(A|X)] .









× [|R− r(X)|A sign(R− r(X))X(2sn)−1I(A sign(R− r(X))XTβn ∈ [−sn/2, sn/2])/pi(A|X)] ,
we assume that s
1/2
n IFn(R,X, A) has a bounded third moment and converges to a random variable
in L2(P ) norm.
Condition (a) requires a separable boundary condition, but this condition can be further re-
laxed to allow XTβ∗ to have positive probability around the boundary and the density vanishes
faster than a linear rate when close to the boundary. Condition (c) usually holds if we estimate
r(x) through some parametric models. In condition (d), sn and Cn are the tuning parameters
to be chosen depending on n, for example, Cn = 1 and sn = n
−1/2. Condition (e) assumes the
convergence of the minimizer associated with the ramp loss. Under these assumptions, we first
show the consistency of ABLO, f̂∗L(x) = x
T β̂. The proof follows the standard M-estimation theory




[|R− r̂(X)|hs {A sign(R− r̂(X))XTβ} /pi(A|X)]+ (2nCn)−1‖β‖2.
It is clear that from assumptions (a), (b) and (c),
sup
β
∣∣∣Pn [|R− r̂(X)|hs {A sign(R− r̂(X))XTβ} /pi(A|X)]
+(2nCn)
−1‖β‖2 − E [|R− r(X)|hs {A sign(R− r(X))XTβ} /pi(A|X)] ∣∣∣→ 0
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almost surely. By condition (b) and (d), E
[|R− r(X)|hs {A sign(R− r(X))XTβ} /pi(A|X)] con-
verges uniformly to E
[|R− r(X)|I {A sign(R− r(X))XTβ < 0} /pi(A|X)], which is equivalent to
E
[
RI(AXTβ < 0)/pi(A|X)]− E[(R− r(X))−]− r(X).
This gives
Pn
[|R− r̂(X)|hs {A sign(R− r̂(X))XTβ} /pi(A|X)]+ (2nCn)−1‖β‖2
→ E [RI(AXTβ < 0)/pi(A|X)]− E[(R− r(X))−]− r(X)
uniformly in β. Since (a) implies f∗L is also the unique minimizer of the latter limit for ‖β‖ = 1,
it yields that any convergent subsequence of β̂ should converge to a limit proportional to β∗.
Therefore, we conclude that β̂/‖β̂‖ converges to β∗ almost surely. Furthermore, by noting
sup
β
∣∣∣P [|R− r̂(X)|hs {A sign(R− r̂(X))XTβ} /pi(A|X)]
−E [|R− r(X)|hs {A sign(R− r(X))XTβ} /pi(A|X)] ∣∣∣→ 0,
we can easily show that ‖β̂ − βn‖ converges to zero almost surely.
To obtain the asymptotic normality for β̂, we follow Koo et al. (2008) by noting β̂ solves
Pn
[
|R− r̂(X)|A sign(R− r̂(X))Xh′s
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|R− r̂(X)|A sign(R− r̂(X))Xh′s
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where Z(β) denotes the random variable A sign(R− r(X))XTβ and FZ(β) is its cumulative distri-










Thus, the asymptotic normality of
√




|R− r̂(X)|A sign(R− r̂(X))Xh′s
{








|R− r(X)|A sign(R− r(X))X I(A sign(R− r(X))X





nsn(β̂ − βn) =
√
nsn(Pn −P)IFn(R,X, A) + op(1).
The asymptotical normality of
√
nsn(β̂ − βn) follows from condition (e).
Lastly, we examine the diagnostic statistics for any estimated decision function, denoted as
δ̂C(f̂) in (2.10), where f̂(x) = xT β̂ is an estimated rule converging to f∗(x) uniformly in x. Note
that we split the data into K folds, f̂ (−k) is estimated without the kth part of data and δ̂(k)C is
computed using the kth part. Let nk denote the sample size of the kth part of data and let Pnk
denote the empirical measure for the k part of data. Define by
δ∗C =
E [I(X ∈ C, Af∗(X) > 0)R/pi(A|X)− I(X ∈ C, Af∗(X) < 0)R/pi(A|X)]
E[I(X ∈ C)]
the subgroup benefit based on the optimal linear rule f∗. Since βn/‖βn‖ → β∗, from condition
(a), we have
β∗TXβTnX/‖βn‖ > 0
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with probability one. Therefore,
δ∗C =
E [I(X ∈ C, Afn(X) > 0)R/pi(A|X)− I(X ∈ C, Afn(X) < 0)R/pi(A|X)]
E[I(X ∈ C)] ,
where fn(X) = β
T
nX.




PnkI(X ∈ C, Af̂ (−k)(X) > 0)R/pi(A|X)
PnkI(X ∈ C)




Since {I(X ∈ C) : C ∈ {C1, ..., Cm}} and
{
Af(X) > 0 : f = XTβ
}
are VC-major classes,
(Pnk −P)I(X ∈ C, Af̂ (−k)(X) > 0)R/pi(A|X)




(Pnk −P)I(X ∈ C, Af∗(X) > 0)R/pi(A|X)
PI(X ∈ C) −
(Pnk −P)I(X ∈ C, Af∗(X) < 0)R/pi(A|X)
PI(X ∈ C)
− E [I(X ∈ C, Af
∗(X) > 0)R/pi(A|X)− I(X ∈ C, Af∗(X) < 0)R/pi(A|X)]




I(X ∈ C, Af̂ (−k)(X) > 0)R/pi(A|X)− I(X ∈ C, Af̂ (−k)(X) < 0)R/pi(A|X)
]
E[I(X ∈ C)]2





Using the smooth condition in (b) and the expansion for β̂
(−k)
around β̂n from the previous asymp-
totic proof, we can show that the difference in the last two terms has a convergence rate faster than
n
−1/2
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where G(C) is a tight Gaussian process indexed by C with mean zero. After averaging over all






→d G˜(C) for some tight




C . Note that these results apply to ABLO f̂L, or other f̂
estimated from minimizing a weighted hinge loss as in O-learning or predictive modeling.
If f∗L is also the global optimal rule, that is f
∗
L = f
∗, then δ∗C > 0 for any C and anyX. Therefore,
the confidence interval for δ∗C will be expected to be within (0,∞) when n is sufficiently large. We
can also construct a test for H0 : δ
∗
C ≥ 0 vs Ha : δ∗C < 0 using this asymptotic distribution.
2.4 Simulation Studies
2.4.1 Simulation Design
For all simulation scenarios, we first generated four latent subgroups of subjects based on 10 feature
variables X = (X1, · · · , X10) informative of optimal treatment choice from a pattern mixture
model. Treatment A = 1 has a greater average effect for subjects in subgroups 1 and 2, and the
alternative treatment −1 has a greater average effect in subgroups 3 and 4. Within each subgroup,
X were independently simulated from a normal distribution with different means and standard
deviation of one. Two settings were considered. In Setting 1, the means of the feature variables for
subjects in the four subgroups were (1, 0.5,−1,−0.5), respectively. In Setting 2, the means were
(1, 0.3,−1,−0.3). Five noise variables U = (U1, · · · , U5) not contributing to R were independently
generated from the standard normal distribution and included in the analyses in order to assess the
robustness of each method in the presence of noise features. The treatments for each subject were
randomly assigned to 1 or −1 with equal probability, and the number of subjects in each subgroup
was equal.
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Three additional feature variables W , V , and S were generated to be directly associated with
the clinical outcome R. Here, W is an observed prescriptive variable informative of the optimal
treatment, V is a prognostic variable predictive of the outcome but not the optimal treatment,
and S is an unobserved prescriptive variable not available in the analysis. The clinical outcome for
subjects in the kth subgroup was generated by
R = 1 + I(A = 1)(δ1k + α1k ∗W + β1k ∗ S) + I(A = −1)(δ2k + α2k ∗W + β2k ∗ S) + V + e,
where e ∼ N(0, 0.25), V , W , and S are i.i.d. and follow the standard normal distribution, δ =
[δlk]2∗4 =
1 0.3 0 0
0 0 1 0.3
, α = [αlk]2∗4 =
 1 0.6 0.5 0.3
0.5 0.3 1 0.6
, and β = 2α. Within each group
k, there is a qualitative interaction between treatment and W as shown in Figure 2.2.
The benefit function of the theoretical global optimal ITR decision function, denoted as f∗, was
computed numerically by simulating the clinical outcome R under both treatment 1 and −1, using
all observed feature variables (i.e., X, W , and V ), and taking the average difference of R under
the true optimal and non-optimal treatments using a large independent test set of N = 100, 000.
In practice, this global optimum may not be attained by a linear rule due to the unknown and
potentially nonlinear true optimal treatment rule. The theoretical optimal linear rule f∗L was
computed numerically using the observed variables and maximizing the value function in the class
of all linear rules under each simulation model (details provided in Appendix Section A.1). The
benefit of f∗L was then computed with a large independent test set of N = 50, 000.
For each simulated data set, predictive modeling (PM), Q-learning, O-learning, and ABLO
were applied to estimate the optimal ITR. For PM, we considered a random forest-based prediction
related to the virtual twins approach of Foster et al. (2011). PM first applies random forest on
R, including all observed feature variables Z = (X,U ,W, V ) and treatment assignments. It next
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Figure 2.2: Clinical outcome (R) versus W with treatment 1 or −1 in each latent group in the
simulation setting. Two vertical dotted lines indicate W = −0.5 and W = 0.5.
































































predicts the outcome for the ith subject given (Zi, Ai = 1) and (Zi, Ai = −1), denoted as R̂1i
and R̂−1i, respectively. The optimal treatment for the subject is sign(R̂1i − R̂−1i). Q-learning
was implemented by a linear regression including all the observed feature variables, treatment
assignments, and their interactions. Benefit of the estimated optimal ITR under each method and
was computed by δ̂C(f̂) in Section 2.2.2.
In the simulations, observed feature variables Z were used in all methods, while the unobserved
prescriptive variable S and latent subgroup membership were not included. Linear kernel was used
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for O-learning and ABLO. Five-fold cross validation was used to select the tuning parameters C and
s. For each method, the optimal treatment selection accuracy and ITR benefit were estimated using
two-fold cross validation with equal size of training and testing sets. The training set was used to
estimate the ITR and the testing set was used to estimate the ITR benefit and accuracy. Bootstrap
was used to estimate the confidence interval of the ITR benefit under the estimated rule. Coverage
probabilities were reported to evaluate the performance of the inference procedure. To evaluate
performance on subgroups, we partitioned W , V , X1, and U1 into three groups based on values
in the intervals (−∞,−0.5), [−0.5, 0.5], or (0.5,∞). We calculated the HTB test for the candidate
variables and tested the difference between the estimated rules and the overall non-personalized
rules.
2.4.2 Simulation Results
Results from 500 replicates are summarized in Table 2.1, 2.2, 2.3, Figure 2.3 and 2.4. For both
simulation settings, ABLO with linear kernel has the largest optimal treatment selection accuracy
regardless of the sample size, and it is also close to the maximal accuracy rate based on the
theoretical best linear rule. In addition, ABLO estimates the ITR benefit closest to the true global
maximal value of 0.678 on the overall sample, and it is almost identical to the benefit estimated
by the theoretical best linear rule when the sample size is large (N = 800 training, 800 testing).
PM, Q-learning, and O-learning all underestimate the ITR benefit, especially when the sample
size is smaller (N = 400 training, 400 testing), and thus they do not attain the maximal value
of the theoretical optimal linear rule. Based on the empirical standard deviation, we also observe
that ABLO is more robust than all other methods. For all methods, as the sample size increases,
the treatment selection accuracy increases and the estimated mean benefit is closer to the true
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optimal value. Furthermore, the estimated ITR benefit increases as the accuracy rate increases.
The coverage probability of the overall benefit of the best linear rule is close to the nominal level
of 95% using ABLO, but less than 95% using other methods. The coverages are not nominal for
O-learning, Q-learning, and PM, since their benefit estimates are biased when the candidate rules
are misspecified (e.g., true optimal rule is not linear). This is because they use a surrogate loss
function that does not guarantee convergence to the indicator function in the benefit function δC(f̂).
The performance of estimation of the subgroup ITR benefit shows similar results, whereby
ABLO outperforms O-learning, Q-learning, and PM in both settings, especially whenW ∈ [−0.5, 0.5],
and W > 0.5. Table 2.2 reports the probability of rejecting H0 : δCk(f
∗
L)− δC3(f∗L) = 0, k = 1 or 2,
using the HTB test with a null distribution of χ22. The rejection rates of the HTB tests of V and U
1
that do not have a difference in ITR benefit across subgroups correspond to the type I error rate.
The type I error rates of ABLO are close to 5%, but conservative for the other three methods. To
examine the power, we test the effect of W on the benefit across subgroups defined by discretizing
W at -0.5 and 0.5. The power of ABLO is much greater than the other three methods especially
when the sample size is small. The other three methods underestimate the benefit function, and
thus the HTB test is conservative and less powerful.
Lastly, we test the difference in the benefit between the ITRs and the non-personalized rule in
the overall sample and the subgroups. Table 2.3 shows that with a sample size of 800, ABLO is the
only method that provides a significantly better benefit than the non-personalized rule with a large
power (> 80%). When the sample size is large (N = 1600), ABLO, Q-learning, and O-learning
have a power of ≥ 88%. As for the subgroups, the ITR estimated by ABLO is more likely to
outperform the non-personalized rule on the subgroups showing a larger true benefit (i.e., when
W > 0.5).
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Additional simulation results varying the strength of the prescriptive feature variable W are
described in Appendix Section A.2. In simulation settings where the conditional outcome model
is correctly specified and all variables are observed, regression-based methods Q-learning and PM
also perform well.
2.5 Application to the STAR*D Study
STAR*D (Rush et al., 2004) was conducted as a multi-site, multi-level, randomized controlled trial
designed to compare different treatment regimes for major depressive disorder when patients fail to
respond to the initial treatment of Citalopram (CIT) within 8 weeks. The primary outcome, Quick
Inventory of Depressive Symptomatology (QIDS) score (ranging from 0 to 27), was measured to
assess the severity of depression. A lower QIDS score indicates less symptoms and thus reflects
a better outcome. Participants with a total QIDS score under 5 were considered to experience a
clinically meaningful response to the assigned treatment and were therefore remitted from future
treatments.
The trial had four levels of treatments (e..g, see Figure 2.3 in Chakraborty and Moodie (2013));
we focused on the first two levels. At the first level, all participants were treated with CIT for a
minimum of 8 weeks. Participants who had clinically meaningful response were excluded from level-
2 treatment. At level-2, participants without remission with level-1 treatment were randomized to
level-2 treatment based on their preference to switch or augment their level-1 treatment. Patients
who preferred to switch treatment were randomized with equal probability to bupropion (BUP),
cognitive therapy (CT), sertraline (SER), or venlafaxine (VEN). Those who preferred augmentation
were randomly assigned to CIT+BUP, CIT+buspirone (BUS), or CIT+CT. If a patient had no
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preference, s/he was randomized to any of the above treatments.
The clinical outcome (reward) is the QIDS score at the end of level-2 treatment. There were 788
participants with complete feature variable information included in our analysis. We compared two
categories of treatments: 1) treatment with selective serotonin reputake inhibitors (SSRIs, alone or
in combination): CIT+BUS, CIT+BUP, CIT+CT, and SER; and 2) treatment with one or more
non-SSRIs: CT, BUP, and VEN. Feature variables used to estimate the optimal ITR included
the QIDS scores measured at the start of level-2 treatment (level 2 baseline), the change in the
QIDS score over the level-1 treatment phase, patient preference regarding level-2 treatment, and
demographic variables (gender, age, race), and family history of depression. As the randomization
to treatment was based on patient preference, we estimated pi(Ai|Xi) using empirical proportions
based on preferring switching or no preference, because patients who preferred augmentation were
all treated with an SSRI and were excluded from the analysis.
We applied four methods to estimate the optimal ITR for patients with MDD who did not
achieve remission with 8 weeks of treatment with CIT. For all methods, we randomly split the
sample into a training and testing set with a 1:1 ratio and repeated the procedure 500 times. The
value function and ITR benefits were evaluated on the testing set. PM, Q-learning, O-learning, and
ABLO are compared in Figure 2.5 and Table 2.4. The non-personalized rules yield a QIDS score of
10.16 for SSRI and 9.60 for non-SSRI, with a difference of 0.56. The ITR estimated by ABLO yields
a QIDS score of 9.32 (sd = 0.23), which is smaller than PM (9.69, sd = 0.38), Q-learning (9.50,
sd=0.35), and O-leaning (9.55, sd = 0.41). The overall ITR benefit estimated by ABLO (1.11, sd
= 0.46) is much larger than PM (0.38, sd = 0.76), Q-learning (0.77, sd = 0.70), and O-leaning
(0.66, sd = 0.82). The ITR benefit based on ABLO is also larger than the non-personalized rule
(1.11 versus 0.56).
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In Figure 2.5, we also present the performance of assigning all subjects to non-SSRI by a blue
dashed line. ABLO is the only method that demonstrates more than 75% of times a greater ITR
value and ITR benefit compared to the non-personalized rule. We performed a one-sided HTB
test in Section 2.2.3 to compare the value function and benefit of the linear ITR with assigning
all to non-SSRI in the overall sample. We observe a difference in benefit of 0.56 points (CI:
(−0.20,∞), p-value= 0.11), and a difference of 0.28 points (CI: (−0.10,∞), p-value= 0.11) in value
function. The confidence intervals and p-values were calculated over repeated cross-validations,
which only accounted for the variability of cross-validations given the STAR*D data. Although
the differences are not statistically significant, they demonstrate some evidence of improvement by
using a personalized treatment strategy that worth future studies.
The final STAR*D linear decision function estimated by ABLO using full data can be expressed
as
f̂(X) =− 12.97 + 0.30 ∗ sex+ 1.27 ∗ white+ 0.79 ∗ black + 2.77 ∗ depression+ 0.05 ∗ age
+ 0.26 ∗ qids.start− 3.40 ∗ qids.slope+ 2.39 ∗ preference,
and the linear ITR is to treat a patient with SSRI if f̂ > 0; otherwise treat with a non-SSRI if
f̂ ≤ 0. The variable “sex” was coded as one for female and “preference” was coded as one for
switch and zero for no preference.
Clinical literature suggests that the baseline MDD severity may be a moderator for treatment
response (Bower et al., 2013). In addition, baseline MDD severity is highly associated with sui-
cidality; thus, patients with severe baseline MDD (QIDS ≥ 16) represent an important subgroup.
We partitioned patients into mild (QIDS ≤ 10), moderate (QIDS ∈ [11, 15]), and severe (QIDS
≥ 16) MDD subgroups. Using ABLO and the HTB test, baseline QIDS score was found to be
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significantly associated with ITR benefit: two subgroups show a large positive ITR benefit (2.22
for the mild group and 2.02 for the severe group), whereas the moderate subgroup shows no benefit
(ITR benefit = −0.18). This result indicates that patients with mild or severe baseline depressive
symptoms (high or low QIDS score) might benefit from following the estimated linear ITR. For
patients who are moderately depressed (QIDS ∈ [11, 15]), the linear ITR estimated from the overall
sample does not adequately fit the data and does not outperform a non-personalized rule. Thus,
we re-fit a linear rule using ABLO for the moderate subgroup only. The re-estimated ITR yields a
lower average QIDS score of 8.93 (sd = 0.35), with a much improved subgroup ITR benefit of 0.60
(sd = 0.70). This analysis demonstrates the advantage of the ITR benefit diagnostic measure, the
HTB test, and the value of re-fitting the ITR on subgroups showing a lack-of-fit.
2.6 Discussion
In this work, we propose a diagnostic measure (benefit function) to compare candidate ITRs,
a machine learning method (ABLO) to estimate the optimal linear ITR, and several tests for
goodness-of-fit. In practice, often not all predictive and prescriptive variables that influence het-
erogeneous responses to treatment are known and collected. Thus, it is unrealistic to expect that
an ITR that benefits each and every individual can be identified. Our practical solution proposes
to evaluate the average ITR effect over the entire population and on vulnerable or important sub-
groups. Although we focus on linear decision functions here, it is straightforward to extend ABLO
to other simple decision functions such as polynomial rules by choosing other kernel functions (i.e.,
polynomial kernel). ABLO can also be applied to observational studies using propensity scores to
replace pi(A|X) under the assumption that the propensity score model is correctly specified. We
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prove the asymptotic properties of ABLO and identify a condition to avoid the non-regularity issue
(in Section 2.3). In practice, when such issue is of concern, adaptive inference (Laber and Murphy,
2011) can be used to construct confidence intervals.
ABLO can consistently estimate the ITR benefit function regardless of misspecification of the
rule by drawing a connection with the robust machine learning approach for approximating the
zero-one loss. We provide an objective diagnostic measure for assessing optimization. In our
method, prescriptive variables mostly contribute to the estimation of the optimal treatment rule
while predictive variables mostly contribute to the development of the diagnostic measure and
assessment of the benefit of the optimal rule. Future work will consider methods to distinguish
these two sets of variables, which potentially overlap.
ABLO is slower than O-learning because it involves iterations of quadratic programming when
applying the DCA. In addition, certain simulations show that the algorithm can be slightly sensitive
to the initial values in extreme cases (examples provided in Figure A.3 in Appendix). However,
our numeric results show that O-learning estimators serve as adequate initial values leading to fast
convergence of the DCA. Another limitation is that the current methods only apply to single-stage
trials. ABLO can be extended to multiple stage setting following a similar backward multi-stage
O-learning in Zhao et al. (2015). The objective function in multi-stage O-learning will be replaced
by the ramp loss and the benefit function will be extended with some attention to subjects whose
observed treatment sequences are partially consistent with the predicted optimal treatment se-
quences. In addition, ABLO does not perform variable selection and therefore it cannot distinguish
important tailoring variables from noise variables. A possible solution is to replace the L2-norm
penalty by L1-norm penalty when minimizing the penalized weighted sum of ramp loss in (2.4).
CHAPTER 2. ESTIMATION AND EVALUATION OF LINEAR INDIVIDUALIZED
TREATMENT RULES TO GUARANTEE PERFORMANCE 40


























































































































































































∗:Dotted-dashed lines represent the benefit (top panels) and accuracy (bottom panels) under the theoretical global
optimal treatment rule f∗. Dashed lines represent the benefit and accuracy under the theoretical optimal linear rule
f∗L. The methods being compared are (from left to right): PM: predictive modeling by random forest; Q-learning:
Q-learning with linear regression; O-learning: improved single stage O-learning (Liu et al., 2014); ABLO:
asymptotically best linear O-learning.
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Table 2.2: Simulation results: probability of rejecting the null hypothesis that the treatment benefit
across subgroups is equivalent by the HTB test
Setting 1. Four region means = (1, 0.5,−1,−0.5).
W X1 V U1
N = 800
PM 0.16 0.05 0.03 0.02
Q-learning 0.18 0.06 0.03 0.03
O-learning 0.21 0.05 0.03 0.03
ABLO 0.42 0.07 0.05 0.06
N = 1600
PM 0.52 0.05 0.05 0.02
Q-learning 0.61 0.05 0.04 0.02
O-learning 0.71 0.04 0.04 0.02
ABLO 0.84 0.05 0.05 0.03
Setting 2. Four region means = (1, 0.3,−1,−0.3).
N = 800
PM 0.12 0.03 0.02 0.02
Q-learning 0.17 0.04 0.03 0.04
O-learning 0.15 0.03 0.03 0.03
ABLO 0.34 0.06 0.04 0.05
N = 1600
PM 0.42 0.06 0.04 0.03
Q-learning 0.56 0.07 0.04 0.03
O-learning 0.57 0.07 0.03 0.03
ABLO 0.74 0.10 0.04 0.05
*: W has strong signal; X1 has weak signal; V and U1 have no signal.
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Setting 2 (N = 1600)
*: Dotted-dashed lines represent the benefit under the theoretical global optimal treatment f∗. Dashed lines
represent the benefit under the theoretical optimal linear rule f∗L. The methods being compared are (from left to
right): PM: predictive modeling by random forest; Q-learning: Q-learning with linear regression; O-learning:
improved single stage O-learning (Liu et al., 2014); ABLO: asymptotically best linear O-learning.
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Table 2.3: Simulation results: Comparison of the ITR to the non-personalized universal rule. The
proportion of rejecting the null that the ITR has the same benefit as the universal rule∗ are reported
for the overall sample and by subgroups.
Setting 1. Four region means = (1, 0.5,−1,−0.5).
Overall W < −0.5 W ∈ [−0.5, 0.5] W > 0.5
N = 800
PM 0.22 0 0.09 0.33
Q-learning 0.37 0.02 0.20 0.40
O-learning 0.39 0.02 0.20 0.43
ABLO 0.86 0.07 0.47 0.78
N = 1600
PM 0.76 0.02 0.38 0.83
Q-learning 0.92 0.05 0.59 0.90
O-learning 0.95 0.06 0.67 0.94
ABLO 0.99 0.08 0.79 0.98
Setting 2. Four region means = (1, 0.3,−1,−0.3).
N = 800
PM 0.18 0.01 0.07 0.27
Q-learning 0.35 0.03 0.17 0.37
O-learning 0.31 0.03 0.17 0.35
ABLO 0.82 0.07 0.43 0.74
N = 1600
PM 0.72 0.03 0.38 0.75
Q-learning 0.88 0.05 0.57 0.86
O-learning 0.90 0.07 0.59 0.86
ABLO 0.99 0.12 0.77 0.97
*: For Setting 1, the mean difference (sd) of the universal rule is 0.09(0.08) for N = 800 and 0.07(0.05) for
N = 1600.
For Setting 2, the mean difference (sd) of the universal rule is 0.11(0.08) for N = 800 and 0.08(0.05) for N = 1600.
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Figure 2.5: STAR*D analysis results: Distribution of the estimated ITR benefit (the higher the
better) and QIDS score (the lower the better) at the end of level-2 treatment for the four methods















































*: The methods being compared are (from left to right): PM: predictive modeling by random forest; Q-learning:
Q-learning with linear regression; O-learning: improved single stage O-learning (Liu et al., 2014); ABLO:
asymptotically best linear O-learning. The blue dashed line indicates non-personalized rule with non-SSRI.
Table 2.4: Results of STAR*D Data Analysis
QIDS score ITR benefit Subgroup ITR benefit by baseline QIDS score
Mean(sd) Mean(sd) QIDS≤ 10 QIDS∈ [11, 15] QIDS≥ 16
PM 9.69(0.38) 0.38(0.76) 1.29(0.82) -0.10(1.02) 0.40(1.67)
Q-learning 9.50(0.35) 0.77(0.70) 2.08(0.68) -0.17(0.92) 1.09(1.62)
O-learning 9.55(0.41) 0.66(0.82) 1.58(0.92) -0.23(0.95) 1.20(1.84)
ABLO 9.32(0.23) 1.11(0.46) 2.22(0.45) -0.18(0.51) 2.02(1.12)
*: lower QIDS score indicates a better outcome; higher benefit indicates a better outcome.
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Chapter 3
Composite Interaction Tree for
Learning Optimal Individualized
Treatment Rules and Subgroups
3.1 Overview
In this chapter, we propose a tree-based learning method, composite interaction tree (CITree), to
simultaneously estimate the optimal individualized treatment rules and identify subgroups with
small and large benefit. In Section 3.2, we propose the statistical method and discuss the algorithm
of CITree in detail. In Section 3.3, we conduct two simulation studies to investigate the performance
of HTB test and compare the performance of the proposed CITree method to existing tree-based
method. In Section 3.4, we apply the method to the REVAMP data and fit a CITree for the whole
sample. Finally, we end this chapter with conclusions and discussions in Section 3.5.
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3.2 Methodologies
In this Chapter, we still focus on single stage two-arm randomized trials and use the same notation
as described in Section 2.2. In clinical practice, linear decision rules are useful due to their trans-
parency and simplicity for interpretation. However, many existing methods may not yield an ITR
with the maximal value function within the class of linear rules, because they focus on optimizing
some surrogate objective function for treatment benefit (2.2). Note that optimizing the surrogate
function only guarantees the optimality when there is no restriction on the functional form of the
rules (i.e., nonparametric rules). In Chapter 2, an asymptotically best linear O-learning (ABLO)
was proposed to guarantee that the estimated decision rule is optimal among all linear rules by
replacing the zero-one loss in (2.10) with the ramp-loss and estimating the optimal linear ITR by
minimizing a penalized loss function (2.4).
Note that ABLO estimates a “global” linear ITR that maximizes the value function applied to
the overall sample. The linear rule may be overly simplified so that it does not lead to the optimal
rule for some subpopulations. Under the ramp loss, the empirical benefit function (2.10) can be
used to identify subgroups with a poor fit under a “global” linear rule and provide an opportunity
to re-fit a “local”, piece-wise linear rule using subjects in the subgroups. Thus, here we propose
the composite interaction tree (CITree) to automatically detect inadequate fit on subgroups and
discover subgroups exhibiting heterogeneous ITR benefit. The central idea of CITree is to improve
the performance of the estimated ITR by re-fitting rules in subgroups with poor performance.
Typically, a tree-based method recursively partitions parent nodes into two child nodes using
a criterion, such as Gini index for CART or G-statistic for interaction tree (IT). Therefore, the
tree growing step is the same from one level to the next and the parent/child nodes have similar
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characteristics. In order to detect both qualitative and quantitative interactions, CITree consists
of two types of parent/child nodes corresponding to qualitative and quantitative splits. Briefly,
for nodes at odd levels, we use ABLO to estimate an optimal ITR using all feature variables to
detect qualitative interaction. For nodes at even levels, we perform a heterogeneity of ITR benefit
(HTB) test to partition subjects in a parent node into two child nodes with homogeneous ITR
benefit, and detect quantitative interaction and lack-of-fit. The motivation for CITree is that the
overall ITR is more likely to be non-optimal for subgroups with a lower benefit. Therefore, the
overall goal is to maximize the value function of the overall population by re-fitting the ITR on
certain subpopulations. Unlike CART which is applied to data with known labels, CITree is an
unsupervised learning that estimates the optimal ITR to assign treatment to future subjects.
Figure 3.1: Diagram of an example Composite Interaction Tree (CITree)∗
∗: For rounded rectangulars, CITree fits fˆ to identify qualitative interaction and estimate the optimal linear ITR
using all feature variables (achieve homogeneous optimal treatment). For ellipses, CITree searches each feature
variable to identify significant quantitative interaction in ITR benefit (achieve homogeneous benefit).
Consider the root node as level 1 in an example CITree in Figure 3.1. The first step is a
qualitative split partitioning subjects into subgroups of homogeneous optimal treatment rules.
Specifically, we estimate an optimal linear ITR using ABLO on the overall sample and obtains a
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linear decision function f̂1(X). Based on the predicted optimal treatment using f̂1(X), subjects
will be partitioned into two nodes at level 2, where on the left are subjects whose optimal treatment
is predicted to be −1, e.g., {i : f̂1(Xi) ≤ 0}, and on the right are those whose optimal treatment
is predicted to be the complementary treatment, e.g., {i : f̂1(Xi) > 0}. The second step is a
quantitative split partitioning each of the nodes at level 2 into two child nodes with homogeneous
ITR benefit. Specifically, we partition the sample space according to a covariate greater than a
threshold, Xs > c, to maximize the difference in ITR benefit between groups in the resulting child
nodes, C1 : Xs ≤ c and C2 : Xs > c, by performing an HTB test. The null hypothesis is
H0 : δC1(f)− δC2(f) = 0,
and the HTB statistic is defined as HTB = [δ̂C1(f̂) − δ̂C2(f̂)]2/Var(δ̂C1(f̂) − δ̂C2(f̂)), where the
subgroup benefit is estimated by (2.10) and the variance of δ̂C1(f̂) − δ̂C2(f̂) given f̂ is estimated
based on a formula in Appendix B.1. We can show that the conditional distribution given f̂ of the
test statistic computed from an independent sample follows a χ2(1) under H0 (such an HTB test
is implemented in the honest CITree as described subsequently). The HTB test is a measure to
evaluate ITR benefit heterogeneity between two child nodes to detect quantitative interactions.
In step 2, we search for the threshold c among grid points c = {c1, · · · , cJ} (e.g., quantiles of the
observed samples) and the covariate space Xs for s = 1, · · · , p, that has the smallest p-value. To
protect against overfitting, we use Benjamin and Hochberg procedure (Benjamini and Hochberg,
1995) to control for the false discovery rate (FDR). Given f̂1(X), a covariate and cut-point, we
partition each node into child nodes. For example, in Figure 3.1, four child nodes at level 3 are
{f̂1(X) ≤ 0;Xs ≤ c1}, {f̂1(X) ≤ 0;Xs > c1}, {f̂1(X) > 0;Xq ≤ c2}, and {f̂1(X) > 0;Xq > c2}.
Note that Xs and Xq are selected independently based on different subgroups, so they can be
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different. Each node not only indicates the estimated optimal treatment, but also partitions patients
based on the magnitude of the benefit gained by following the estimated optimal rule, and chooses
the most significant cut point after adjusting for the FDR. If no HTB test is significant at the
controlled FDR level, CITree stops partitioning the parent node.
The next step is to consider re-fitting the ITR using only subjects in each child node and denote
the decision functions as f̂2. If the value function is improved by the re-fitted ITR, CITree further
partitions the current node into subgroups of different optimal treatment based on f̂2. CITree stops
growing when no HTB test is significant, or the number of observations in the node is less than
a pre-specified number, or the re-fitted ITR does not improve the value function (stopping rules
are described in Algorithm 1). The resulting ITR for a K terminal nodes tree takes the form of∑
k I(X ∈ R̂k)f̂k(X), where R̂k indicates subjects in the kth terminal node following a particular
path on the tree, and f̂k(X) = β̂0k +X
T β̂k is the final linear ITR fitted from ABLO for the node
k. The fitted ITR contains binary partitioning of the covariate space through R̂k and a linear
combination of covariates through f̂k(X) to balance interpretability and flexibility. Algorithm 1
illustrates the procedure.
An advantage of CITree is the simultaneous detection of qualitative and quantitative interactions
if both are present. Step 1 identifies qualitative interaction to estimate the optimal treatment
using ABLO and step 2 identifies quantitative interaction through HTB test. Note that after
performing step 1 to partition subjects into homogeneous groups with similar optimal treatment,
step 2 identifies quantitative heterogeneity of ITR effects and diagnoses potential subgroups with
a low benefit, which suggests a poor fit of the ITR estimated from the whole sample from upper
level. By performing a re-fit on such subgroups, CITree always leads to a higher or equal value
function compared to using the full sample. The step of re-fitting ITR offers patients whose optimal
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Algorithm 1 Composite Interaction Tree (CITree)
Fit an ITR for the whole sample using ABLO and obtain an initial rule f̂1.
Step 1: for l = 1, 3, 5, · · ·
• Partition each parent node at level l into two child nodes: {f̂k ≤ 0} and {f̂k > 0}.
Step 2: for l = 2, 4, 6, · · ·
• Search for the most significant HTB test among covariate space at grid points.
• Split each parent node into two child nodes if the adjusted HTB test is significant for
variable Xs at split point c: {Xs ≤ c } and {Xs > c}.
• Re-fit f̂ for each child node if it improves the value function.
Stopping rules
• If number of subjects in the node is less than a pre-specified number, the node will not be
split.
• If no HTB test is significant at even level of nodes, the node will not be split.
• If re-fitting ITR at the odd level of nodes does not improve the value function, the node
will not be split.
The final ITR is a piece-wise linear function denoted as
∑
K I(X ∈ R̂k)f̂k(X).
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treatments are estimated incorrectly at an upper level an opportunity to rectify and search for their
true optimal treatment. Another advantage of CITree is to use a linear combination of feature
variables rather than one variable (as done in IT or QUINT) to build a tree, which may lead to
identifying the optimal rule in fewer steps and with improved accuracy.
CITree uses the same sample for two types of splits. When the sample size is large and overfitting
is of primary concern, honest CITree can be used where the HTB test is performed on a hold-out
sample not involved in estimating ITRs. Specifically, honest CITree separates the whole sample
into two subsets. The training set is only involved to estimate ITR, while the ITR benefit and HTB
test are computed using the hold-out sample. This procedure guarantees using an honest measure
of the performance (Athey and Imbens, 2016) to determine the tree growth.
3.3 Simulation Studies
We perform extensive simulation studies to evaluate the CITree algorithm. In the first simulation
study, we examine whether the algorithm can successfully identify quantitative interaction between
covariates and treatment. In a simple simulation setting, we evaluate the performance of HTB test
by type I and type II error rates. The type I error rate represents the probability that CITree
performs a quantitative split in a group of subjects with no heterogeneous ITR benefit. The type
II error rate represents the probability of failure to detect a true ITR heterogeneity. In the second
simulation study, we compare the overall performance of CITree with existing tree-based machine
learning methods by assessing the overall ITR benefit in a more complex tree setting, and investigate
to what extent that CITree can recover the true tree structure.
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3.3.1 Simulation Study 1
Simulation data sets were generated based on the tree structure in the left panel of Figure 3.2. The
simulation setting is inspired by real world applications where patients consist of heterogeneous
subgroups with both quantitative and qualitative interactions. In this setting, treatment 1 is more
beneficial for subjects in the right node and treatment −1 is more beneficial for subjects in the left
node. Within the subgroup where treatment −1 benefits more, there exists a subgroup (X1 ≤ −0.5)
that has a greater treatment effect comparing to the rest of subjects (X1 > −0.5). The true optimal
treatment decision function is f1(X) = X1 +X2, where X1 and X2 are feature variables generated
i.i.d from N(0, 1). For the left node, a quantitative interaction was simulated between X1 and the
optimal treatment, which leads to two child nodes, one with a larger ITR benefit, and the other
with a smaller ITR benefit. We compared four settings in the simulations, where A is randomly
assigned as 1 or −1 with equal probability, and the clinical outcome R is generated by
R = η(X) +Aφ(X) + ,  ∼ N(0, 0.25),
φ(X) = 0.5I(f1(X) > 0)− I(f1(X) ≤ 0)
[
0.5 + αI(X1 ≤ −0.5)
]
. (3.1)
In the above model, the first term η(X) is the main effect not contributing to defining the true
ITR; and the second term Aφ(X) indicates that the optimal ITR should have the same sign as
f1. For setting 1 and 2, η(X) = X1 − 0.5X2 and no other feature variables were considered in the
analysis. For setting 3 and 4, η(X) = X1−0.5X2+0.5X3, variables X3 and X4 were generated i.i.d
following N(0, 1) and not contributing to the optimal ITR. In these two settings, all four feature
variables were considered when fitting CITree. Parameter α in model (3.1) determines the effect
size of the quantitative interaction, which is set to be 0.5 for setting 1 and 3, and 1 for setting 2
and 4. True benefits for subjects in terminal nodes under the true optimal rule are summarized in
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Figure 3.2.
Figure 3.2: CITree structure for generating data of simulation studies (left panel: simulation study
1; right panel: simulation study 2)
∗: For setting 1 and 3, α = 0.5; for setting 2 and 4, α = 1.
In each simulation, honest CITree randomly partitioned the whole sample into two subsets in
step 1 and step 2 of the CITree algorithm. We examined different sample size ratio for step 1 and
step 2 (2:1, 1:1, and 1:2) in order to assess the performance of the fitted ITR and HTB test. Step
1 was applied to the first data set to obtain f̂1, which was used to assign subjects in the second set
into two nodes at level 2 based on their predicted optimal treatment. Thus subjects in step 1 and
step 2 were independent, and HTB tests were evaluated on two nodes at level 2. For each feature
variable, we searched from the values of 1/4 quantile to 3/4 quantile, with an increase of 0.1. We
split a node when at least one of the HTB tests is significant at the controlled FDR level. By the
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simulation design, we can use the left node to evaluate the type II error and the right node to
evaluate the type I error rate. The sample size was N = 500, 1, 000, and 2, 000. We controlled FDR
at rate 0.05 and 0.1. To evaluate the performance of ITR, we simulate an independent validation
data set for each setting with N = 10, 000. We report the overall benefit and accuracy rate on the
validation set.
Results from 1, 000 replicates were summarized in Table 3.1. The type I error rates of HTB
test are adequately controlled at the FDR rate for CITree. For honest CITree, type I error rates
of HTB test are controlled at the FDR rate for setting 1 and setting 2. For setting 3 and 4, the
type I errors were better controlled when the sample size for step 2 is larger. The power of both
CITree and honest CITree increase as the sample size and the effect size of quantitative interaction
increase. Given the same total sample size, the power of HTB test increases as the sample size of
step 2 increases, which leads to a greater power of CITree over honest CITree. However, a smaller
sample size of step 1 will affect the performance of fitted ITR. Table 3.1 shows that the accuracy
rates and the overall benefits of the honest CITree decrease as the subset of step 1 gets smaller. To
balance the performance of step 1 and step 2, we used a 1:1 ratio in the rest of analyses.
When HTB tests were significant, we report the rate of choosing the correct variable for splitting.
Given the correct variable was selected, we also report the rate of choosing the correct split point.
Similar to Dusseldorp and Van Mechelen (2014), the correct split point is defined as being in the
interval [c − 0.2, c + 0.2], where c is the true split point. For setting 2 and 4 with a large benefit
heterogeneity between terminal nodes 1 and 2 and a sample size of 1,000 or 2,000, both CITree and
honest CITree can almost always identify the quantitative interaction, choose the right variable,
and at the right split point. In other settings of reduced benefit heterogeneity and sample size, the
ability to identify the correct tree structure is modest.
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Table 3.1: Simulation study 1 results: type I error rate and power for HTB tests
N Type I error Power Correct variable Correct point Accuracy Benefit
FDR 0.05 0.1 0.05 0.1 0.05 0.1 0.05 0.1
Honest CITree sample sizes for step 1 and 2 are 2 to 1
Setting 1 500 0.033 0.062 0.308 0.409 0.938 0.939 0.682 0.708 0.985 (0.013) 1.239 (0.194)
1000 0.043 0.072 0.528 0.642 0.992 0.988 0.842 0.841 0.989 (0.010) 1.242 (0.136)
2000 0.031 0.069 0.879 0.921 0.998 0.998 0.981 0.979 0.990 (0.015) 1.244 (0.102)
Setting 2 500 0.033 0.066 0.860 0.919 0.995 0.991 0.945 0.944 0.983 (0.014) 1.498 (0.202)
1000 0.046 0.071 0.993 0.997 1 1 0.983 0.983 0.987 (0.015) 1.498 (0.143)
2000 0.026 0.065 1 1 1 1 1 1 0.988 (0.017) 1.500 (0.110)
Setting 3 500 0.071 0.141 0.275 0.373 0.800 0.780 0.641 0.639 0.980 (0.013) 1.218 (0.209)
1000 0.069 0.115 0.490 0.616 0.920 0.890 0.834 0.827 0.985 (0.012) 1.224 (0.149)
2000 0.057 0.116 0.83 0.903 0.983 0.970 0.924 0.924 0.989 (0.015) 1.235 (0.108)
Setting 4 500 0.073 0.138 0.798 0.879 0.961 0.944 0.887 0.889 0.978 (0.014) 1.477 (0.217)
1000 0.069 0.115 0.985 0.994 0.996 0.995 0.983 0.982 0.985 (0.010) 1.483 (0.156)
2000 0.052 0.116 1 1 1 1 0.997 0.997 0.988 (0.011) 1.495 (0.109)
Honest CITree sample sizes for step 1 and 2 are 1 to 1
Setting 1 500 0.037 0.071 0.410 0.535 0.976 0.966 0.812 0.805 0.982 (0.014) 1.220 (0.153)
1000 0.025 0.053 0.768 0.840 0.995 0.994 0.932 0.932 0.988 (0.009) 1.234 (0.111)
2000 0.036 0.072 0.967 0.980 1 1 0.993 0.993 0.990 (0.012) 1.238 (0.080)
Setting 2 500 0.041 0.077 0.965 0.982 0.999 0.999 0.974 0.975 0.980 (0.014) 1.478 (0.159)
1000 0.025 0.057 1 1 1 1 0.998 0.998 0.986 (0.013) 1.490 (0.118)
2000 0.029 0.063 1 1 1 1 1 1 0.989 (0.010) 1.498 (0.082)
Setting 3 500 0.072 0.129 0.376 0.496 0.888 0.849 0.769 0.755 0.975 (0.014) 1.208 (0.171)
1000 0.060 0.115 0.666 0.765 0.953 0.945 0.880 0.874 0.984 (0.010) 1.222 (0.120)
2000 0.052 0.100 0.962 0.981 0.991 0.988 0.974 0.973 0.988 (0.012) 1.235 (0.089)
Setting 4 500 0.065 0.131 0.947 0.970 0.993 0.987 0.938 0.938 0.974 (0.015) 1.466 (0.181)
1000 0.054 0.114 1 1 0.999 0.999 0.998 0.998 0.982 (0.010) 1.481 (0.124)
2000 0.053 0.104 1 1 1 1 1 1 0.987 (0.009) 1.495 (0.091)
Honest CITree sample sizes for step 1 and 2 are 1 to 2
Setting 1 500 0.040 0.072 0.532 0.624 0.996 0.984 0.851 0.847 0.977 (0.017) 1.205 (0.132)
1000 0.025 0.046 0.892 0.922 0.998 0.997 0.962 0.963 0.985 (0.010) 1.230 (0.097)
2000 0.030 0.067 0.994 0.996 1 1 0.998 0.998 0.989 (0.013) 1.236 (0.070)
Setting 2 500 0.042 0.070 0.993 0.999 1 0.999 0.989 0.989 0.974 (0.017) 1.462 (0.140)
1000 0.023 0.046 1 1 1 1 1 1 0.983 (0.011) 1.488 (0.099)
2000 0.034 0.069 1 1 1 1 1 1 0.987 (0.011) 1.494 (0.073)
Setting 3 500 0.071 0.127 0.511 0.618 0.937 0.908 0.808 0.806 0.966 (0.018) 1.187 (0.148)
1000 0.058 0.109 0.818 0.881 0.979 0.967 0.926 0.926 0.979 (0.010) 1.215 (0.104)
2000 0.061 0.102 0.994 0.997 0.998 0.997 0.988 0.988 0.986 (0.008) 1.231 (0.076)
Setting 4 500 0.066 0.129 0.983 0.993 0.997 0.997 0.972 0.972 0.964 (0.019) 1.446 (0.156)
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1000 0.063 0.106 1 1 1 1 0.999 0.999 0.978 (0.010) 1.474 (0.107)
2000 0.061 0.103 1 1 1 1 1 1 0.985 (0.009) 1.489 (0.079)
CITree
Setting 1 500 0.032 0.054 0.753 0.838 0.997 0.996 0.920 0.920 0.990 (0.010) 1.242 (0.107)
1000 0.027 0.050 0.983 0.994 1 1 0.985 0.985 0.991 (0.012) 1.245 (0.082)
2000 0.032 0.063 1 1 1 1 0.997 0.997 0.990 (0.021) 1.240 (0.066)
Setting 2 500 0.030 0.051 1 1 1 1 0.997 0.997 0.988 (0.008) 1.500 (0.112)
1000 0.028 0.046 1 1 1 1 1 1 0.990 (0.010) 1.503 (0.083)
2000 0.031 0.068 1 1 1 1 1 1 0.988 (0.018) 1.498 (0.070)
Setting 3 500 0.049 0.102 0.648 0.776 0.965 0.938 0.885 0.882 0.986 (0.008) 1.239 (0.117)
1000 0.038 0.086 0.950 0.974 0.991 0.991 0.967 0.966 0.990 (0.008) 1.241 (0.086)
2000 0.039 0.089 1 1 1 1 0.999 0.999 0.990 (0.016) 1.240 (0.068)
Setting 4 500 0.060 0.104 1 1 0.999 0.999 0.994 0.994 0.985 (0.008) 1.498 (0.123)
1000 0.036 0.086 1 1 1 1 1 1 0.989 (0.009) 1.499 (0.088)
2000 0.040 0.082 1 1 1 1 1 1 0.990 (0.012) 1.501 (0.067)
3.3.2 Simulation Study 2
In this study, we investigate the performance of different methods in a more complex tree setting.
We compared CITree and honest CITree (1:1) with MIDAs (Laber and Zhao, 2015), interaction
trees (IT) and QUINT. Unlike other tree-based methods (e.g., IT or QUINT), which first fit a large
tree and then prune the tree to avoid overfitting, the CITree does not require pruning since splitting
only occurs when the HTB test is significant using an independent testing sample at controlled FDR
rate (i.e., honest CI Tree).
In our real data application described in Section 3.4, we found that although the benefit of a
global linear rule was greater than the effect of the non-personalized rule on the overall sample, it
was worse for some subgroups. In many cases, the performance of the ITR can be improved by
refitting the rule within specific subgroups. In order to mimic such real data cases, simulation data
sets were generated based on a tree structure in the right panel of Figure 3.2, where treatment 1
is more beneficial for subjects in terminal nodes T3, T4 and T5, and treatment −1 is better for
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subjects in terminal nodes T1 and T2. ITR benefits are the largest for subjects in terminal nodes
T1 and T5. Similar to simulation study 1, we generated four feature variables, X1 to X4, and a
continuous outcome R by (3.1), but with
φ(X) = I(f1(X) > 0)− I(f1(X) ≤ 0)
{
I(X1 ≤ −0.3)
+ 0.5I(X1 > −0.3)
[
I(f2(X) ≤ 0)− I(f2(X) > 0)[I(X3 > 0.3) + 0.5I(X3 ≤ 0.3)]
]}
.
We define f1(X) = X1 + X2 − 0.5 and f2(X) = X3 + X4. In setting 5, η(X) = X1 − 0.5X2 +
0.5X3 − 0.5X4. In setting 6, η(X) = X1 − 0.5X2 + 0.5X3 − 0.5X4 + 0.5X5, where X5 and X6 are
also i.i.d. with a standard normal distribution. In setting 6, both X5 and X6 were included when
fitting CITree.
For each simulated data set, CITree, honest CITree, IT, MIDAs, and QUINT were applied to
estimate optimal ITR and estimate its benefit. QUINT partitions the overall population into three
classes, where treatment −1 is more beneficial to subjects in class 1, treatment 1 is more beneficial
to subjects in class 2 and treatment effects are similar for subjects in class 3. Assignment of optimal
treatment for individuals depends on the treatment effect of the class they belong to. For those
predicted to be in class 3 where the difference of two treatments is not significant, the optimal
treatment is determined by the sign of the average effect in the terminal node where the subject
belongs to. Interaction tree is a classification/regression tree (CART) where the splitting criterion
is based on a t-test of difference between treatment groups. MIDAs is a decision tree method, which
splits the parent node into child nodes depending on whether the value function will dramatically
increase. For the honest CITree, we randomly partitioned all subjects to two subsets with 1:1 ratio
and perform step 1 and step 2 of the algorithm on separate data sets. Other design features of the
simulation study is the same as simulation 1.
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∗: The red dashed lines represent values based on true optimal rules
Results from 100 replicates are summarized in Table 3.2, 3.3, 3.4, 3.5, and 3.6, and Figure
3.3, 3.4, and 3.5. For both settings, CITree has the best overall performance (Table 3.2 , reported
empirical mean and standard deviation) with the highest optimal treatment allocation accuracy and
the largest overall benefit when the sample size is 500 or 1, 000. As the sample size increases to 2, 000,
honest CITree performs almost the same as CITree, but with significantly shorter computation time.
CITree is the only method that achieves a greater than 90% treatment allocation accuracy when the
sample size is 500. QUINT and MIDAs perform worse than the other methods, with less than 85%
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Table 3.2: Simulation study 2 results: comparing overall performance of five methods
Optimal Treatment Allocation Accuracy Rate
Setting N QUINT MIDAs IT Honest CITree CITree
Setting 5 500 0.815 (0.020) 0.815 (0.027) 0.856 (0.023) 0.898 (0.030) 0.936 (0.023)
1000 0.818 (0.018) 0.827 (0.017) 0.889 (0.013) 0.931 (0.023) 0.947 (0.016)
2000 0.820 (0.014) 0.835 (0.013) 0.913 (0.010) 0.946 (0.019) 0.938 (0.020)
Setting 6 500 0.804 (0.027) 0.798 (0.025) 0.841 (0.028) 0.884 (0.027) 0.917 (0.027)
1000 0.819 (0.022) 0.818 (0.017) 0.881 (0.017) 0.917 (0.029) 0.941 (0.019)
2000 0.819 (0.016) 0.830 (0.013) 0.905 (0.012) 0.941 (0.018) 0.942 (0.015)
Overall ITR Benefit
Setting N QUINT MIDAs IT Honest CITree CITree
Setting 5 500 1.207 (0.054) 1.196 (0.090) 1.301 (0.052) 1.405 (0.059) 1.473 (0.049)
1000 1.218 (0.045) 1.240 (0.055) 1.383 (0.037) 1.466 (0.044) 1.493 (0.036)
2000 1.230 (0.027) 1.273 (0.040) 1.444 (0.024) 1.493 (0.041) 1.483 (0.035)
Setting 6 500 1.174 (0.089) 1.146 (0.081) 1.256 (0.079) 1.381 (0.056) 1.441 (0.055)
1000 1.218 (0.064) 1.222 (0.059) 1.366 (0.044) 1.439 (0.058) 1.485 (0.042)
2000 1.235 (0.035) 1.269 (0.041) 1.434 (0.031) 1.486 (0.042) 1.488 (0.033)
∗: The true overall benefit for both settings is 1.64.
treatment estimation accuracy and the lowest estimated overall benefit. When the total sample size
is 2, 000, the estimated overall benefits of the CITree and honest CITree are close to the true benefit
of 1.64, and the treatment allocation accuracy is near 95%. Based on the simulation designs, the
true terminal node membership of each subject can be determined. Thus, we further examined the
optimal treatment allocation accuracy for subjects in each terminal node in Table 3.3. For subjects
in terminal nodes T2, T3, and T4, who are most likely to be mis-allocated, both CITree and honest
CITree perform much better than other methods in terms of accuracy. MIDAs performs relatively
well on T3 and T4 comparing to CITree and honest CITree. Honest CITree and CITree perform
adequately for subjects in T2 with accuracy greater than 72%, while QUINT and MIDAs perform
the worst with the accuracy rates ranging from 20% to 45%. CITree and Honest CITree have a
substantially greater benefit on T3 and T4 when N = 1, 000 and 2, 000 than other methods due to
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re-fitting ITR on these subgroups. QUINT, honest CITree and CITree perform well for subjects in
terminal node 1 (T1) with accuracy greater than 96%. IT and MIDAs are the only two methods
with lower than 95% accuracy rates for T1 when N = 500. MIDAs, IT, honest CITree and CITree
have a better performance (accuracy rates over 89.5%) in terminal 5 (T5) comparing to QUINT
(accuracy rates around 86%).
In Figure 3.4 and 3.5, we visualize the estimated optimal treatment for each patient in the
validation set averaged over 100 repetitions. The optimal treatment boundaries (solid blue lines)
were projected onto feature variables X1 and X2 for terminal nodes T1, T2, and T5, and onto X3
and X4 for T2, T3, and T4. In both figures, the color of dots represents the average estimated
optimal treatment (with treatments coded as “1” or “−1”) for that subject in the validation set
by a certain method based on 100 simulated data sets. The blue solid line is the true optimal
treatment boundary for qualitative interaction. The blue dashed line is the true boundary of
quantitative interaction (high vs low ITR benefit). Subjects between the solid and dashed lines
form the subgroup which is most easily mis-allocated by a sub-optimal method. CITree and honest
CITree perform better as shown in Figure 3.4, because they use a combination of feature variables
to perform qualitative split. Other methods only consider one variable for each split and therefore
do not capture a non-rectangular boundary. In Figure 3.5, our methods also perform better than
alternatives, due to performing a quantitative split. An advantage of CITree over other trees that
only fits qualitative interaction is that: subgroup with small benefits is the group that most likely
to have an inaccurate predicted optimal treatment. For example, MIDAs uses the overall value
function in all subjects as criterion, thus may not have adequate fit on this subgroup. In contrast,
CITree specifically identifies this subgroup with poor fit and re-fit an ITR locally using data from
this subgroup only.
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To examine the complexity of the trees fitted by five methods, we report number of terminal
nodes for each method in Table 3.4. The average number of terminal nodes for honest CITree and
CITree is around 5, which is the true number of nodes. The average number of tree levels is also
close to the the truth (5 levels). QUINT and MIDAs also generate relatively simple trees with
an average number of 6 to 7 terminal nodes. IT has the most complicated tree, after pruning it
still terminates with 10 to 25 terminal nodes (more complicated with larger sample size). With a
relatively simple tree, CITree has better performance than IT with a more complicated structure.
To further explore performance on recovering the tree structure, we report positive predictive
value (PPV) and subgroup benefit for the terminal nodes predicted by CITree and honest CITree.
The PPV of a terminal node represents the proportion of subjects who truly belong to the node
among those who are predicted to be in a terminal node. For T3 and T4, the sample size in both
nodes are small and the difference in benefit are low, thus the results with T3 and T4 combined
are reported. When the sample size is large at 1, 000 or 2, 000, for both CITree and honest CITree,
the PPV of T1 is high at a rate above 95%; the PPV of T2 and T3 + T4 is above 85%; the PPV
of T5 is the lowest, where some subjects who belong to T2, T3 and T4 are misallocated to T5.
When sample size is small (N = 500), the PPV of CITree is greater than that of the honest CITree
for each predicted terminal. The subgroup benefit of the predicted terminal nodes is consistent
with the PPVs, where subjects in T1 performs the best. The subgroup benefit of predicted T5 is
lower than the true value of 2.0, which suggests that some subjects from low benefit nodes were
misallocated to this terminal node.
In addition, we examined whether the correct variable was selected for splitting from level 2 to
level 3. When the sample size is 1, 000, more than 95% times, the correct variable X1 was selected
and more than 95% times an adequate split point (true value −0.3, considered as adequate in the
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range [−0.5,−0.1]) was identified. When sample size is 2, 000, both CITree and honest CITree can
select the correct variable at an adequate cut point.
Regarding the computational speed, the honest CITree takes 15 seconds and CITree takes 1.5
minutes for N = 1, 000 on a PC with 3.8GHz CPU. The honest CITree is much faster than the
CITree since it only uses half of the sample in each step. They are both faster than QUINT
(2 minutes), which used five bootstrapped samples in the bootstrap-based pruning procedure.
The computation of searching the best HTB test for CITree is fast given the derived variance
formula. The computational time of estimating ITR for CITree after level 1 is also fast since the
sample size reduces dramatically in lower levels of the tree. QUINT was implemented via the R
package “quint” (Dusseldorp et al., 2016). R code for IT is available at http://biopharmnet.
com/subgroup-analysis-software/. R code for MIDAs was from the authors. R codes for fitting
CITree are available upon request.
3.4 Application to the REVAMP Study
REVAMP (Kocsis et al., 2009) is a two-phase, 12-week randomized trial, which aimed to compare
the efficacy of combining psychotherapy with medication to medication alone among chronic MDD
patients who didn’t fully respond to initial treatment of an antidepressant medication. Among 808
patients who entered phase I, 491 patients didn’t achieve remission and therefore entered phase II.
They were randomly assigned to receive (1) continued pharmacotherapy and augmentation with
cognitive behavioral analysis system of psychotherapy (MEDS+CBASP), (2) continued pharma-
cotherapy and augmentation with brief supportive psychotherapy (MEDS+BSP), or (3) continued
optimized pharmacotherapy (MEDS) alone with 2:2:1 ratio.
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The clinical outcome of interest is the 24-item Hamilton Depression Rating Scale (HAM-D)
total score at the end of phase II treatment. A lower HAM-D score indicates less symptoms and
thus a better response. We compared two categories of treatments: 1)Medication plus psychother-
apy (MEDS+THERAPY); and 2) Medication alone (MEDS). Five feature variables were used to
estimate the optimal ITR: gender(Male=1; Female=0), age (median = 47), Quick Inventory of De-
pression Symptoms (QIDS, a score to measure the symptoms of depression, a lower score indicates
better clinical outcome) score at the end of phase I (median = 8), the relative change of QIDS
score over phase I (median = −0.44, calculated as change of QIDS score over phase I divided by
baseline QIDS score), and current alcohol use (Yes=1). We estimated pi(Ai|Xi) from the data by
the empirical proportions of the treatment. There were 418 participants with complete feature
variable information included in our analysis, where 336 received medication and therapy, and 82
patients received medication only.
We applied CITree, IT, QUINT, and MIDAs to estimate the optimal ITR for MDD patients who
did not achieve remission with phase I treatment. For all methods, we randomly split the sample
into a training set and testing set with 1:1 ratio and repeated the procedure 100 times. QUINT did
not identify any individual variable that has a qualitative interaction with the treatment, therefore
it returns a non-personalized treatment rule, that is, to treat all patients with medication and
therapy. The mean HAM-D score is 12.50 for MEDS+THERAPY and 12.81 for MEDS only group.
Three other methods estimated an individualized treatment rule. Figure 3.6 compares the overall
performance of CITree to IT and MIDAs. The ITR estimated by CITree yields an average HAM-D
score of 12.17 (sd=1.41), which is smaller than IT (12.97, sd=1.33), and MIDAs (12.54, sd=0.95),
indicating a better performance of CITree (Table 3.7). The overall ITR benefit estimated by CITree
(0.96, sd=2.43) is much larger than that based on IT (-0.64, sd=2.26) and MIDAs (0.21, sd=2.48),
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and also greater than QUINT (an overall benefit of 0.31). Both IT and MIDAs perform worse than
the non-personalized rule.
We present the fitted CITree on the full data in Figure 3.7. Subjects are first partitioned into
two groups with predicted optimal treatment as MEDS + THERAPY or MEDS only based on
the sign of first level decision rule, f̂1(X). For the right node with MEDS only as the optimal
treatment, subjects are then partitioned into a high benefit group (QIDS change> −0.21) and a
low benefit group (QIDS change≤ −0.21) based on the relative change of QIDS score at phase 1.
CITree stops growing for the high benefit node (T4) and re-fit f̂2(X) for the low benefit group
and forms another two terminal nodes T2 and T3. On the right side of the tree, no heterogeneity
in benefit was found and CITree stops growing after the first split. The final optimal treatment
decision rule omitting variables with negligible coefficients can be summarized as −I(f̂1(X) ≤
0) + I(f̂1(X) > 0)
[
I(QIDs.change > −0.21) + I(QIDs.change ≤ −0.21) × sign(f̂2(X))
]
, where
f̂1(X) = −0.5 + alcohol and f̂2(X) = 0.5 − gender. For the first level ITR, current alcohol
use dominates the optimal ITR, and in level 3 gender is the most important feature variable.
Thus current alcohol use and gender are identified to manifest a qualitative interaction. A recent
study by Gunter et al. (2011) also showed alcohol dependence is useful for selecting treatments
in a Nefazodone CBASP Trial for major depression. Relative change of QIDS score manifests a
quantitative interaction to distinguish patients with a high and low benefit.
CITree divides patients into four terminal nodes. For subjects who don’t use alcohol (T1),
adding therapy is more beneficial than treated by medication alone. For those with current al-
cohol use and phase I QIDS relative change > −0.21, medication alone is more beneficial com-
pared to adding therapy. Males with current alcohol use and larger relative change of phase I
QIDS decrease are more likely to achieve a better treatment outcome (lower HAMD score) with
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MEDS+THERAPY; while females with current alcohol use and larger relative change of phase I
QIDS decrease are more likely to perform better by MEDs only.
3.5 Discussion
In this work, we propose a tree-based learning method (CITree) to estimate interpretable ITRs and
simultaneously identify subgroups with large benefit to guide treatment decision making for the
patients. CITree performs qualitative interaction and quantitative interaction splits and retains the
re-fitted linear rule in each node only if the new rule improves the subgroup and overall benefit,
so it is guaranteed to outperform ABLO. The proposed algorithm fits a linear rule in each node to
estimate an ITR and thus the resulting rule is piece-wise linear. When desirable, polynomial rule
can also be considered. We have shown that using a linear combination of feature variables may
be more powerful in identifying qualitative interaction comparing to exploring a single variable
in turn. QUINT and IT do not have this feature, which may have contributed to their inferior
performance both in simulations and real data application. Other possible reasons for their inad-
equate performance include using surrogate objective function for splitting criterion (e.g., t-test)
and imbalanced treatment group size.
The composite interaction tree method has several limitations. First, it is slower comparing to
ABLO, since it requires re-fitting ABLO at different child nodes. Faster computational algorithm is
worth investigating in the future, e.g., parallel computing for finding child nodes in different parent
nodes. In addition, like other tree-based methods, the composite interaction tree could be unstable
depending on the first few splits (although the fitted tree was fairly stable in REVAMP example).
An extension is to consider ensemble methods in line with random forest. However, such methods
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may lose the advantage on interpretability. Lastly, an important extension is to develop a dynamic
tree-based method for multi-stage studies such as sequential multi-stage randomization trials.
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Table 3.3: Simulation study 2 results: classification accuracy among subjects truly belong to each
terminal node
Setting N Method T1 T2 T3 T4 T5
Setting 5 500 QUINT 0.981 (0.044) 0.374 (0.337) 0.665 (0.343) 0.784 (0.280) 0.865 (0.061)
MIDAs 0.932 (0.056) 0.315 (0.170) 0.779 (0.174) 0.803 (0.151) 0.912 (0.044)
IT 0.949 (0.038) 0.591 (0.157) 0.642 (0.270) 0.787 (0.185) 0.927 (0.049)
Honest CITree 0.969 (0.018) 0.740 (0.122) 0.674 (0.215) 0.755 (0.193) 0.965 (0.021)
CITree 0.974 (0.015) 0.788 (0.099) 0.841 (0.143) 0.932 (0.100) 0.975 (0.014)
1000 QUINT 0.990 (0.025) 0.283 (0.357) 0.753 (0.356) 0.856 (0.265) 0.870 (0.049)
MIDAs 0.956 (0.036) 0.252 (0.143) 0.854 (0.131) 0.866 (0.113) 0.924 (0.038)
IT 0.968 (0.022) 0.685 (0.102) 0.666 (0.206) 0.853 (0.099) 0.941 (0.025)
Honest CITree 0.973 (0.014) 0.765 (0.099) 0.835 (0.141) 0.928 (0.124) 0.975 (0.014)
CITree 0.978 (0.012) 0.802 (0.076) 0.892 (0.094) 0.974 (0.039) 0.977 (0.012)
2000 QUINT 0.996 (0.008) 0.242 (0.352) 0.755 (0.372) 0.907 (0.223) 0.873 (0.045)
MIDAs 0.975 (0.021) 0.200 (0.124) 0.872 (0.125) 0.899 (0.090) 0.936 (0.023)
IT 0.982 (0.013) 0.742 (0.074) 0.720 (0.155) 0.886 (0.066) 0.953 (0.019)
Honest CITree 0.979 (0.010) 0.795 (0.088) 0.898 (0.081) 0.970 (0.056) 0.976 (0.015)
CITree 0.974 (0.011) 0.822 (0.070) 0.787 (0.170) 0.916 (0.116) 0.980 (0.011)
Setting 6 500 QUINT 0.978 (0.047) 0.437 (0.350) 0.605 (0.359) 0.685 (0.333) 0.846 (0.079)
MIDAs 0.911 (0.049) 0.304 (0.166) 0.780 (0.191) 0.791 (0.154) 0.895 (0.046)
IT 0.933 (0.046) 0.594 (0.180) 0.603 (0.268) 0.756 (0.217) 0.913 (0.062)
Honest CITree 0.966 (0.020) 0.725 (0.119) 0.594 (0.204) 0.706 (0.205) 0.961 (0.028)
CITree 0.973 (0.013) 0.747 (0.112) 0.773 (0.169) 0.875 (0.158) 0.965 (0.022)
1000 QUINT 0.988 (0.036) 0.325 (0.359) 0.729 (0.353) 0.838 (0.268) 0.864 (0.061)
MIDAs 0.941 (0.040) 0.248 (0.155) 0.820 (0.160) 0.842 (0.132) 0.925 (0.034)
IT 0.968 (0.020) 0.659 (0.118) 0.643 (0.228) 0.835 (0.116) 0.936 (0.029)
Honest CITree 0.970 (0.017) 0.750 (0.103) 0.772 (0.175) 0.873 (0.155) 0.966 (0.018)
CITree 0.975 (0.013) 0.790 (0.096) 0.879 (0.082) 0.961 (0.053) 0.975 (0.014)
2000 QUINT 0.995 (0.013) 0.236 (0.344) 0.763 (0.357) 0.877 (0.263) 0.879 (0.039)
MIDAs 0.963 (0.029) 0.200 (0.124) 0.854 (0.129) 0.898 (0.081) 0.938 (0.023)
IT 0.981 (0.013) 0.719 (0.091) 0.693 (0.176) 0.869 (0.089) 0.950 (0.017)
Honest CITree 0.976 (0.011) 0.793 (0.074) 0.876 (0.086) 0.962 (0.053) 0.973 (0.016)
CITree 0.974 (0.012) 0.816 (0.065) 0.848 (0.123) 0.946 (0.064) 0.978 (0.010)
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Table 3.4: Simulation study 2 results: total nodes or levels of tree based methods
QUINT MIDAs IT Honest CITree CITree
Setting N Nodes Nodes Nodes Levels Nodes Levels Nodes
Setting 5 500 6.09 (0.93) 5.80 (0.91) 9.26 (1.54) 4.81 (0.87) 4.18 (1.18) 5.30 (0.61) 4.99 (1.03)
1000 6.01 (1.00) 6.32 (1.03) 14.55 (2.13) 5.34 (0.54) 5.22 (1.09) 5.47 (0.72) 5.65 (1.55)
2000 5.89 (0.99) 6.58 (0.79) 22.60 (3.86) 5.42 (0.61) 5.72 (1.48) 5.68 (0.91) 6.47 (1.84)
Setting 6 500 6.10 (0.85) 6.22 (0.89) 9.95 (1.86) 4.73 (1.00) 4.30 (1.55) 5.41 (0.89) 5.43 (1.67)
1000 5.98 (1.08) 6.69 (0.99) 16.05 (2.89) 5.34 (0.86) 5.20 (1.36) 5.56 (0.80) 5.73 (1.52)
2000 5.64 (0.98) 6.98 (0.90) 24.13 (4.27) 5.57 (0.76) 5.89 (1.58) 5.77 (1.13) 6.45 (2.01)
Table 3.5: Simulation study 2 results: PPVs of predicted terminal nodes by CITree
Setting N Method T1 T2 T3+T4 T5
Setting 5 500 Honest CITree 0.919 (0.126) 0.761 (0.234) 0.832 (0.198) 0.748 (0.072)
CITree 0.969 (0.056) 0.875 (0.137) 0.934 (0.063) 0.779 (0.072)
1000 Honest CITree 0.970 (0.047) 0.871 (0.136) 0.945 (0.059) 0.759 (0.061)
CITree 0.977 (0.037) 0.918 (0.096) 0.966 (0.040) 0.774 (0.060)
2000 Honest CITree 0.980 (0.011) 0.930 (0.043) 0.970 (0.044) 0.768 (0.073)
CITree 0.982 (0.010) 0.809 (0.156) 0.923 (0.074) 0.777 (0.071)
Setting 6 500 Honest CITree 0.911 (0.131) 0.700 (0.232) 0.800 (0.163) 0.740 (0.067)
CITree 0.964 (0.050) 0.851 (0.100) 0.890 (0.092) 0.754 (0.063)
1000 Honest CITree 0.956 (0.080) 0.850 (0.117) 0.904 (0.091) 0.753 (0.063)
CITree 0.976 (0.041) 0.907 (0.057) 0.952 (0.042) 0.773 (0.069)
2000 Honest CITree 0.977 (0.017) 0.915 (0.045) 0.961 (0.029) 0.767 (0.063)
CITree 0.982 (0.008) 0.855 (0.138) 0.938 (0.063) 0.781 (0.061)
CHAPTER 3. COMPOSITE INTERACTION TREE FOR LEARNING OPTIMAL
INDIVIDUALIZED TREATMENT RULES AND SUBGROUPS 72
Table 3.6: Simulation study 2 results: subgroup benefits of predicted terminal nodes by CITree
Setting N Method T1 T2 T3+T4 T5
Setting 5 500 Honest CITree 1.959 (0.400) 0.610 (0.406) 0.996 (1.132) 1.521 (0.311)
CITree 1.964 (0.233) 0.957 (0.316) 0.811 (0.305) 1.638 (0.207)
1000 Honest CITree 1.958 (0.225) 0.804 (0.357) 0.852 (0.427) 1.550 (0.203)
CITree 1.957 (0.149) 0.928 (0.240) 0.768 (0.272) 1.598 (0.176)
2000 Honest CITree 1.956 (0.149) 0.904 (0.246) 0.774 (0.289) 1.569 (0.200)
CITree 1.977 (0.098) 0.932 (0.154) 0.631 (0.210) 1.591 (0.157)
Setting 6 500 Honest CITree 1.959 (0.558) 0.380 (0.531) 0.814 (0.666) 1.427 (0.296)
CITree 1.990 (0.303) 0.893 (0.322) 0.766 (0.434) 1.513 (0.204)
1000 Honest CITree 1.915 (0.323) 0.710 (0.338) 0.786 (0.389) 1.567 (0.271)
CITree 1.964 (0.163) 0.903 (0.252) 0.804 (0.330) 1.630 (0.185)
2000 Honest CITree 1.937 (0.173) 0.855 (0.267) 0.768 (0.310) 1.542 (0.181)
CITree 1.983 (0.114) 0.940 (0.158) 0.718 (0.219) 1.601 (0.155)
∗: True benefits of Setting 5 are 2.00 for T1, 0.91 for T2, 1.95 for T5 and 0.70 for T3+T4.
True benefits of Setting 6 are 2.00 for T1, 0.89 for T2, 1.97 for T5 and 0.77 for T3+T4.






































∗: Distribution of estimated ITR benefit (the higher the better) and QIDS score (the lower the better) at the end of
stage 2 treatment for three methods (based on 100 cross-validation)
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Table 3.7: Overall performance of three methods in the REVAMP Study
Method MIDAs IT CITree
Value 12.54 (0.95) 12.97 (1.33) 12.17 (1.41)
Benefit 0.21 (2.48) -0.64 (2.26) 0.96 (2.43)
Figure 3.7: CITree for optimal individualized treatment decision (the REVAMP Study)
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Chapter 4




In this chapter, we propose an integrative learning method to estimate the optimal individualized
treatment rule by synthesizing evidence across multiple trials. In Section 4.2, we introduce the
rationale and algorithm of the proposed integrative machine learning method. In Section 4.3, we
derive the underlying Bayesian rules for the proposed method. In Section 4.4, we perform extensive
simulation studies to show improvement as compared to existing machine learning methods for sin-
gle studies. In Section 4.5, we apply the proposed method to the EMBARC trial using information
from HEAL trial. Finally, we end this chapter with discussions and possible extensions in Section
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4.6.
4.2 Methodologies
In Chapter 2 and 3, we focus on proposing methods for learning simple ITRs on a single randomized
controlled trial. However, an ITR learned by a single study aims to optimize the performance on
the study, which may not generalize to a future sample. A method that can use information from
multiple studies may provide an ITR that represents a more general population and therefore has
better reproducibility. Because not all of the same feature variables are collected in each study, one
cannot directly combine study data and perform a single analysis. Taking weighted averages of the
estimated ITR decision functions also does not apply because each ITR is obtained by maximizing
the empirical value function, which has a complex, nonlinear relationship with the decision function.
In this section, we propose novel integrative learning methods to combine ITRs from RCTs that
collect different subsets of baseline feature variables.
4.2.1 Integrative Learning for High-Resolution ITR Using Coarsened ITRs
First consider how to enhance learning a high-resolution ITR dependent on a rich set of features in a
comprehensive trial by using coarsened ITRs that have been learned from smaller trials with subsets
of feature variables. Let (Xi, Ai, Ri), i = 1, ...., n, be the richest set of baseline feature variables,
treatments, and treatment outcomes collected on the ith participant in a comprehensive trial,
denoted as study 0. The randomization probability of ith participant is denoted as P (Ai|Xi) =
pii. For other K trials, only a subset of features, denoted by Zk, is collected by design. The
observed data from these trials consist of (Zjk, Ajk, Rjk) for the jth patient in the kth trial, and
P (Ajk|Zjk) = pijk for its randomization probability, with j = 1, ..., nk, k = 1, ...,K.
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The richest feature set X defines the high-resolution ITR (denoted by sign(f0(X))), in terms
of conditional response given X. Features Zk as subsets of X define coarser, low-resolution ITR
(denoted by sign(fk(Zk))), in terms of conditional response given Zk. Our key rationale is that each
low-resolution fk still maintains certain optimality when applied to patients in the comprehensive
trial but only using features available in Zk. Although fk is fit by maximizing the average value
of the conditional response given coarsened groups (stratified by conditioning on Zk), such that it
may not be optimal for every individual in the finest group stratified by X, fk is informative of f0
in the following sense: randomly select a patient from subpopulations stratified by different values
of Zk, and apply to this patient the finest optimal ITR f0 based on X. We should expect that most
times, the treatment recommendations from f0 should be the same as those based on fk because fk
should maximize the conditional response given Zk averaged over all subjects (definition of value
function). Based on this rationale, we propose the following method to integrate evidence from the
smaller/auxiliary trials to improve learning the optimal ITR from the comprehensive trial.
First, for k = 1, ...,K, we use outcome weighted learning (e.g. ABLO) and kth study data
to obtain the optimal rule dependent on the kth study features, denoted as sign(f˜k(Zk)). The
corresponding benefit function is denoted by δ˜(f˜k(Zk)). To simplify the notation of benefit function,
we will use δ˜k(Zk) to represent δ˜(f˜k(Zk)) in the following sections. That is, for any future subject
including the subject in the high-resolution study (study 0) whose value for the feature variable
Zk is zk, the learned rule based on the kth study concludes that the optimal treatment assignment
should be 1 if f˜k(zk) > 0 and -1, otherwise. Under the this optimal treatment assignment, the
expected benefit is δ˜k(zk).
Hence, for each subject i in study 0, in addition to the observed trial data (Ai,Xi, Ri), we also
know from the kth study evidence that his/her optimal treatment rule should not be significantly
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different from sign(f˜k(Zik)) and that the expected benefit should not be far from δ˜k(Zik), where
Zik is the set of the feature variables used in the kth study so is part of Xi. Next, we integrate this
external information to learn the optimal treatment rule using the data from study 0. Specifically,
we introduce an additional regularization to incorporate f˜k as prior information in the learning




















where λk is a tuning parameter to be selected from data, and δ˜ik = δ˜k(Zik). A straightforward
choice is to let δik be the approximate benefit of using f˜k to assign treatments available based on
ABLO. Note that the first term in (4.1) is the empirical value function associated with f0. The
second term is a regularization term such that the more consistent the signs of f0 and f˜k, the larger
the value. Thus, the regularization ensures that the derived treatment rule is consistent with the
learned rule from the kth trial.





































2I(Aif˜k(Zik) > 0)− 1
}
. Thus, maximizing (4.1) is equivalent
to maximizing another empirical version of the value function, but the outcome for individual i is
augmented as R˜i instead of Ri. Hence, this optimization can be solved by minimizing a surrogate
ramp loss function, as in ABLO. The tuning parameter λk can be selected by cross-validation with
a maximal value function. δ˜ik can be estimated by parametric or non-parametric models using
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the kth trial data and predicting the estimated benefit on the subjects of study 0. Specifically,
in this work, we apply a linear regression model on the kth trial data with assigned treatment,
baseline feature variables and their interactions to predict clinical outcome for each subject with
both treatment 1 and -1 given its feature variables. The benefit is then estimated by the difference
between the predicted outcome given the estimated optimal treatment and the predicted outcome
given the alternative treatment for subjects in study 0. Note that λk can be tuned separately for
different coarsened ITR k. In practice, since δik will be estimated separately for each study k, one
can keep λk the same across different studies to ease computational burden on choosing tuning
parameters.
4.2.2 Integrative Learning for Coarsened ITRs Using High-Resolution ITR
In clinical settings with limited resources (e.g., when cost constraint does not permit the collection
of brain imaging data), an ITR that depends only on easily assessed clinical variables can be
practically useful. Thus, we propose an integrative learning approach to enhance coarsened ITRs
by using evidence generated from existing studies with high-resolution ITR.
The key rationale is that the average benefit of the high-resolution ITR f0 evaluated in a
subgroup stratified by Zk should be the same as the average benefit of the coarsened ITR fk.
First, we obtain the optimal treatment rule, denoted by sign(f˜0(X)), and its benefit function,
denoted by δ˜0(X), using study 0. To incorporate this information to improve the rule learning in
study k, k = 1, ...,K. For each k, we consider estimating fk by maximizing the following objective














I(fk(Zik)f˜0(Xi) > 0), (4.2)
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where λk is a tuning constant and weight δ˜i = δ˜0(Xi). Again, δi can be the benefit of assigning
treatment to subject i using f˜0 estimated from ABLO. In (4.2), the first component is the empirical
value for each ITR fk involving the kth trial data. The second component encourages fk and f˜0 to
yield the same treatment recommendation (same sign) as much as possible, especially for subjects
with a large benefit δ˜i.















2I(Aif˜0(Xi) > 0)− 1
)
I(Aifk(Zik) > 0).
We again augment the original data set by combining data from both study k and study 0; however,
for subject i in study 0, instead of using Ri as the reward outcome in the augmentation term, we
use R˜i = λknkn
−1δ˜i(2I(Aif˜0(Xi) > 0) − 1), which is less variable than Ri. For optimization, we
just augment the data from kth study, (Zjk, Ajk, Rjk), with additional data from study 0 with
(Zik, Ai, R˜i). Therefore, we can apply the standard learning method to learn the optimal ITR
using this integrated data set. Additionally, λk weighs the importance of this augmentation and
will be chosen by cross-validation.
4.2.3 Extension to Blockwise Feature Domains in a Single Trial
With the development of new data collection techniques, multiple sources of data may be collected
from different domains. In practice, it is common that the data entails blockwise feature entries
(Xiang et al., 2013), due to cost or primitive protocol of data collection. For example, in the
EMBARC trial, some subjects have complete clinical, neuropsychiatric measures and brain imaging
measures, while others are lack of the entire domain of brain imaging data.
Assume that the blockwise feature pattern is completely random and noninformative. The data
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Figure 4.1: An example for data collected with blockwise feature domains
*: white color indicates the measures for that domain are missing, other colors indicate the measures that are
complete. In this case, X includes feature variables from domain 1, 2, 3, and 4; Z1 includes variables from domain
1 and 2; Z2 includes variables from domain 1, 2, and 3; ZK includes only variables from domain 1.
from this single study can be treated as collected from multiple trials based on the domains of
feature variables that are collected. More specifically, study 0 consists all subjects with complete
feature variable measures, and subjects that have the same block of feature variables measured will
be considered as from an independent trial. In this way, the total number of small studies, K, is the
total number of block patterns. For example, in Figure 4.1, there are K sub-studies. In study 0 with
complete feature variables X, using methods in Section 4.2.1, one can learn a high-resolution ITR
f˜0(X); while in study k, a coarsened ITR f˜k(Zk) will be estimated given the available covariates
Zk. Compared to using study data 0 alone, the integrative learning offers an opportunity to use
all collected data efficiently. Hence, our proposed method to integrate treatment rules learned in
K studies can be used to improve learning optimal treatment rule using the data from study 0.
4.3 Theoretical Results
In this section, we derive the underlying Bayesian rules of the integrative learning methods. To this
end, we assume that the asymptotic limits of f˜k(Zk) and δ˜k(Zk) in (4.1) are, fk(Zk) and δk(Zk),
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over f0(X), where E0(·) denotes the expectation under the joint distribution of (R,X) in study
0, and pi(a|X) = P (A = a|X) in study 0. Using the standard result from the outcome weighted















































E0[R|A = 1,X]− E0[R|A = −1,X] +
K∑
k=1
λk(E0[Rk|Ak = 1,Zk]− E0[Rk|Ak = −1,Zk])
)
.
In other words, the Bayesian rule is to essentially combine all conditional treatment effects given
Zk from all the auxiliary studies with treatment effect given X. Here, λk is used to weigh the
effect size from the kth study. The first term has the same sign as the theoretical optimal high-
resolution ITR using the rich feature set X. The second term aggregates coarsened treatment
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recommendations and benefits that are fitted from the smaller feature sets Zk. Therefore, the
integrated ITR converges to an ITR that prescribes treatment with larger weighted conditional
benefits across trials. Thus, in this sense the integrated ITR borrows information from all trials.
Under the assumption that the direction of the expected treatment difference given X in study 0
is the same as the average treatment difference given Zk, f˜0 is Fisher consistent.
Furthermore, we remark that when λk is close to zero, the derived Bayesian rule approximates
the true optimal treatment rule. However, in finite samples of study 0, the optimal rule estimated
from one single study is likely to be different from the true optimal rule for some subjects due
to limited information available to learn a fully nonparametric rule. Therefore, by allowing λk to
be non-zero and determined in a data-driven way, one can use additional information from other
studies to correct the finite sample bias in study 0 and improve the precision by including more
samples available in auxiliary studies.


























where Ek(·) is the expectation with respect to (Rk,Zk) in study k, g0(·) and gk(·) are the density
functions for Zk in study 0 and study k, respectively. This expression, up to a constant independent
of fk, is equivalent to,
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Therefore, the Bayesian rule for this integrative learning is
sign(f∗k (Zk)) = sign
(




(E0[R|A = 1,Zk]− E0[R|A = −1,Zk])
)
,
which is a weighted combination of the conditional treatment effects given Zk from study k and
study 0. In particular, λk gives the weight to integrate evidence from study 0. Additionally, if the
conditional treatment effects are in the same direction or even have the same magnitude across the
trials, the above Bayesian rule is the same as the optimal rule for study k. However, using the
combined treatment effects to estimate the integrative rule has a better precision in finite sample
due to including more data from study 0.
As a remark, δk(Zk) or δ(X) can be replaced by any other functions of the feature variables, or
even a constant of one. In this case, the Bayesian rules are not necessarily based on the combined
conditional treatment effects, but is the combination of the treatment effect in the study of interest
and the evidence from other trials depending on the optimal rules learned in those trials.
4.4 Simulations
4.4.1 Simulation Design
The simulation model is inspired by real-world applications where multiple RCTs are conducted
at different locations or different time (Justice et al., 1999). In the simulation studies, the patient
population consists of a mixture of patients. For all trials, we assume that within each mixing
subgroup the conditional distribution of R given X is the same, but the mixing proportion is
different across trials. For example, a trial conducted in one location may consist of more elderly
patients than another trial in another location, but the distribution of outcome given age and other
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feature variables follow the same distribution within the subgroup of elder or younger patients.
In the simulation model, three feature variables, (X1, X2, X3), informative of optimal treatment
choice, were generated from four latent subgroups of subjects with probabilities (p1, p2, p3, p4).
Within each subgroup, X1, X2, and X3 were independently simulated from a normal distribution
with different means, (1, 0.5,−1,−0.5), and standard deviation of one. The treatment for each
subject was randomly assigned to 1 or −1 with equal probability. The clinical outcome for subjects
in the kth subgroup was generated by
R = 1 + I(A = 1)(δ1k + α1k ∗W ) + I(A = −1)(δ2k + α2k ∗W ) + α1k ∗ S + 0.5 ∗ V ∗A+ ,
where  ∼ N(0, 0.25), V , W , and S are i.i.d. and follow the standard normal distribution, δ =
[δlk]2∗4 =
0.8 0.3 0 0
0 0 0.8 0.3
, α = [αlk]2∗4 =
 1 0.6 0.5 0.3
0.5 0.3 1 0.6
. Treatment A = 1 has a
greater average effect for subjects in subgroups 1 and 2, and the alternative treatment −1 has a
greater average effect in subgroups 3 and 4. Here, W is an observed prescriptive variable within each
subgroup, V has qualitative interaction with treatment and therefore it is directly informative of
the selection of optimal treatment, and S is an unobserved prognostic variable with the same main
effect within each subgroup. One noise variable N1 not contributing to the clinical outcome was
independently generated from the standard normal distribution. In order to apply our method, we
generated one high-resolution data set (data set 0), including all the observed feature variablesX =
(X1, X2, X3,W, V,N1), and one low-resolution data set (data set 1), with onlyZ1 = (X1, X2, X3, V ).
To mimic real-world situation, we set the probabilities of belonging to each latent subgroups as
(0.4, 0.1, 0.4, 0.1) for data set 0, and (0.2, 0.3, 0.2, 0.3) for data set 1.
In order to test the generalizability of the proposed method, we evaluate the estimated ITR
on different target populations, aiming to simulate different settings of patient recruitment in
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the future target population where the ITR will be implemented. The total population consists
of a mixture of patients, with the same conditional distribution of R given X within subgroup
as described above. Each setting has mixing proportion, specifically, the ratio of the validation
settings are (0.25, 0.25, 0.25, 0.25), (0.2, 0.2, 0.3, 0.3), (0.5, 0, 0.5, 0), and (0, 0.5, 0, 0.5) for settings 1
to 4. Validation setting 3 and 4 represent extreme cases when only subgroups with large or small
benefits are collected. To maintain the simplicity and interpretability of the ITRs, we only consider
linear rules in the following.
4.4.2 Simulation Results
4.4.2.1 Integrative learning for improving high-resolution ITR using coarsened ITRs
In this section, we evaluate the performance of the integrative learning for high-resolution ITR
improved by coarsened ITRs. For each simulation, data set 1 is used to learn a coarsened ITR
with only 4 variables, namely X1, X2, X3, and V . The ITR learned by integrative learning uses
all the 6 observed feature variables (X1, X2, X3,W, V,N1) and includes the coarsened ITR as prior
information in the learning algorithm. The weight δ˜i1 of subject i is estimated by a linear regression
model using the data set 1 including treatment assignment, feature variables and their interactions,
and predict the estimated benefit on the study 0. In the real data applications, when estimating
the benefit is not possible (e.g., only the coarsened ITR is available but not the individual-level
data of study 1), we assign the same weight for each individual in the high-resolution data set,
which is equivalent to setting δ as one for each subject. We compared the integrative learning
results (both weighted by estimated benefit and equally weighted) to ABLO using only data set 0
(ABLO-H) with feature variables X or data set 1 (ABLO-L) with feature variables Z1. The sample
size was 200 for both data set 0 and 1. Cross validation was used to select the tuning parameters λ.
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To evaluate the performance of ITRs, we simulate independent validation data with four different
settings as described above, each setting with N = 10, 000. We report the overall benefit, value
and classification accuracy on the four validation settings.
Table 4.1: Mean and standard deviation of overall benefit, value and accuracy rates using integrative
learning for high-resolution ITRs comparing to ITRs by ABLO on single studies
ABLO-H ABLO-L Int-Equal Int-Ben
Benefit Setting 1 0.806(0.053) 0.819(0.063) 0.830(0.045) 0.841(0.036)
Setting 2 0.807(0.052) 0.818(0.060) 0.830(0.045) 0.841(0.035)
Setting 3 0.894(0.046) 0.893(0.068) 0.909(0.047) 0.920(0.031)
Setting 4 0.711(0.068) 0.747(0.065) 0.745(0.055) 0.752(0.045)
Value Setting 1 0.668(0.027) 0.675(0.033) 0.680(0.023) 0.686(0.019)
Setting 2 0.665(0.026) 0.670(0.030) 0.676(0.022) 0.682(0.018)
Setting 3 0.833(0.024) 0.832(0.035) 0.840(0.025) 0.846(0.017)
Setting 4 0.501(0.034) 0.519(0.032) 0.518(0.028) 0.522(0.022)
Accuracy Setting 1 0.810(0.027) 0.817(0.033) 0.823(0.024) 0.830(0.019)
Setting 2 0.812(0.028) 0.820(0.033) 0.825(0.025) 0.831(0.020)
Setting 3 0.812(0.022) 0.808(0.038) 0.818(0.026) 0.825(0.017)
Setting 4 0.806(0.037) 0.827(0.039) 0.827(0.032) 0.832(0.028)
∗: ABLO-H is estimated by ABLO using high-resolution data only;
ABLO-L is estimated by ABLO using low-resolution data only;
Int-Equal is estimated by integrative learning for high-resolution ITR with equal weights for all subjects;
Int-Ben is estimated by integrative learning for high-resolution ITR weighted by estimated benefit.
Results from 100 replicates are summarized in Table 4.1 and Figure 4.2. For all the validation
settings, ITRs estimated by integrative learning using both trial data outperform ITRs learned
by ABLO using single trial data with larger optimal treatment selection accuracy, larger overall
benefit and estimated value function. With more information used to estimate an ITR, the ITRs
by integrative learning are more likely to be generalized to a future sample. Also, integrative
learning weighted by estimated benefit performs better than using equal weights in the simulation
since the estimated benefits are also useful information in learning the ITR. By integrating useful
CHAPTER 4. INTEGRATIVE LEARNING TO SYNTHESIZE INDIVIDUALIZED
TREATMENT RULES ACROSS MULTIPLE TRIALS 87



















































































































*: ABLO-H is estimated by ABLO using high-resolution data only;
ABLO-L is estimated by ABLO using low-resolution data only;
Int-Equal is estimated by integrative learning for high-resolution ITR with equal weights for all subjects;
Int-Ben is estimated by integrative learning for high-resolution ITR weighted by estimated benefit.
information, the benefit and value function estimated by integrative learning are also more efficient
compared to ABLO with smaller standard deviations.
4.4.2.2 Integrative learning for improving coarsened ITRs using high-resolution ITR
In this section, we evaluate the performance of the integrative learning for coarsened ITR using
high-resolution ITR. The simulation data sets we generated are exactly the same as the above
section. The only difference is that the ITRs learned by integrative learning is a low-resolution ITR
without variable W and N1. We assume the those two variables are not observed in the validation
settings. Therefore, the high-resolution ITR cannot be used to predict the optimal ITR in the
validation set. For each simulation, data set 0 is used to learn a high-resolution ITR. And then the
high-resolution ITR was used as prior information to integrate the coarsened ITR. We compared
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the integrative learning results (both weighted by estimated benefit and equally weighted) to the
coarsened ITR by ABLO using data set 1 (ABLO-L) with low-resolution feature variables Z1. We
were not able to compare the result with ABLO-H using data set 0, because we assumed complete
feature variable information was not observed in the validation sets and only low-resolution ITRs
were fitted in the simulation.
Table 4.2: Mean and standard deviation of overall benefit, value and accuracy rates using integrative
learning for low-resolution ITRs comparing to ITRs by ABLO on single studies
ABLO-L Int-Equal Int-Ben
Benefit Setting 1 0.820(0.057) 0.844(0.033) 0.858(0.023)
Setting 2 0.820(0.057) 0.843(0.036) 0.858(0.025)
Setting 3 0.888(0.066) 0.919(0.039) 0.928(0.029)
Setting 4 0.748(0.060) 0.757(0.046) 0.778(0.030)
Value Setting 1 0.675(0.030) 0.688(0.018) 0.695(0.013)
Setting 2 0.671(0.029) 0.683(0.018) 0.690(0.013)
Setting 3 0.829(0.034) 0.845(0.020) 0.849(0.016)
Setting 4 0.519(0.030) 0.524(0.022) 0.534(0.014)
Accuracy Setting 1 0.817(0.030) 0.830(0.021) 0.838(0.016)
Setting 2 0.820(0.032) 0.833(0.021) 0.842(0.015)
Setting 3 0.805(0.035) 0.823(0.021) 0.828(0.017)
Setting 4 0.827(0.036) 0.834(0.029) 0.848(0.021)
∗: ABLO-L is estimated by ABLO using low-resolution data only;
Int-Equal is estimated by integrative learning for low-resolution ITR with equal weights for all subjects;
Int-Ben is estimated by integrative learning for low-resolution ITR weighted by estimated benefit.
Simulation results from 100 repetitions are summarized in Table 4.2 and Figure 4.3. For all
the validation settings, ITRs learned by integrative learning (Int-Equal and Int-Ben) using data
sets from both trials outperform the coarsened ITR learned by ABLO using single data set of
low-resolution feature variables. Also, integrative learning weighted by estimated benefit performs
better than integrative learning using equal weights, indicating the estimated benefit does help
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*: ABLO-L is estimated by ABLO using low-resolution data only;
Int-Equal is estimated by integrative learning for low-resolution ITR with equal weights for all subjects;
Int-Ben is estimated by integrative learning for low-resolution ITR weighted by estimated benefit.
in learning the integrative ITR. By borrowing useful information, the integrative learning is also
more efficient comparing to ABLO-L by reducing the standard deviations for about 50% in esti-
mation of overall benefit and value function. By borrowing information from high-resolution ITR,
the integrative ITR retains the simplicity by including only four feature variables, but improves
the performance by incorporating additional information from another RCT with more feature
variables.
Additional simulation studies were performed in Appendix Section C.1, where simulation models
are slightly different across different trials.
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4.5 Application to the EMBARC trial
EMBARC (Trivedi et al., 2016) is a two-phase, multi-site, randomized trial, which was designed to
discover biosignatures associated with response to treatment for MDD. In the first stage, partici-
pants were randomized to an 8-week treatment of sertraline (one kind of SSRI, Selective Serotonin
Reuptake Inhibitor) or placebo. We will focus on the first stage in our analysis. The primary out-
come, Hamilton Depression Rating Scale (HAM-D) was measured at week 8 to assess the severity
of depression. The clinical outcome (reward) we use in the analysis is the change in HAM-D score
from baseline to week 8, where a larger value of the change corresponds to better treatment re-
sponse (a greater reduction in symptom). There are 242 participants with complete baseline clinical
feature variables and outcome. The clinical feature variables are gender, race, age, baseline HAM-
D score, and baseline Quick Inventory of Depressive Symptomatology (QIDS) score. Among all
242 patients, only 138 have neuroimaging and behavioral phenotyping measures. In this example,
138 patients with complete clinical measures, behavioral phenotyping and neuroimaging measures
were considered as study 0. We performed univariate analysis as a screening step by a linear re-
gression model including the feature variable, assigned treatment and their interaction to assess
all tier 1 behavioral phenotyping and brain imaging measures. The most informative behavioral
phenotyping measure “Effect of Flanker interference on accuracy” and functional magnetic reso-
nance imaging (fMRI) measure “Pregenual cingulate (seed) to right amygdala conflict adaptation
coupling” were selected with p-value of the interaction term less than 0.1. Flanker accuracy effect
is a measure of interference effects, with higher scores indicating an increased interference effects
(i.e., reduced cognitive control). The selected fMRI measure is the difference of the connectivities
between Pregenual cingulate and Right amygdala during incongruent minus congruent frames, dur-
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ing the emotion recognition task (ERT), which is a standard neuropsychiatric test. Both variables
were included when estimating a high-resolution ITR using EMBARC data.
Healing Emotion After Loss (HEAL, Shear et al., 2016) is the low-resolution study we used
to improve the performance of ITR for EMBARC study. HEAL is a single-phase, multi-site,
randomized trial. Patients with complicated grief were randomized to receive citalopram (also
one kind of SSRI), placebo, citalopram+psychotherapy, or placebo+psychotherapy. Since a large
proportion of patients with complicated grief are also suffering from MDD, we use the subgroup of
patients with current MDD and were randomized to either citalopram or placebo in the analysis.
Based on the study design, the primary outcome for HEAL was the change of QIDS score from
baseline to week 12. There are 74 patients satisfied our inclusion criteria and used in the analysis.
To learn a coarsened ITR, we used age, gender and baseline QIDS score in the HEAL study as the
feature variables.
We applied the same four methods as the simulation studies to estimate the optimal high-
resolution ITR (SSRI or placebo) for patients with complete feature variable information in the
EMBARC study (132 subjects). For all methods, we randomly split the EMBARC sample into
a training and testing set with a 2:1 sample size ratio and repeated the procedure 100 times.
We bootstrapped the HEAL sample to learn a coarsened ITR for every repetition. The value
function and ITR benefits were evaluated on the testing set. Results for ABLO using the HEAL
data (ABLO-L), ABLO using the EMBARC complete feature variables (ABLO-H), integrative
learning with equal weight (Int-Equal) and integrative learning with estimated benefit (Int-Ben)
are compared in Table 4.3 and Figure 4.4. The non-personalized rules yield a change in HAM-D
score of 7.48 for SSRI and 5.84 for placebo, with a difference of 1.64. The ITR estimated by Int-Ben
yields a HAM-D change score of 7.71 (sd = 1.27), which is larger than Int-Equal (7.64, sd = 1.36),
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ABLO-H (7.63, sd = 1.40), and ABLO-L (7.24, sd=1.60). The overall ITR benefit estimated by
Int-Ben (2.24, sd = 1.98) is larger than Int-Equal (2.04, sd = 2.18), ABLO-H (2.04, sd = 1.98),
and ABLO-L (1.33, sd = 2.49). The ITR benefit based on Int-Ben is also much larger than the
non-personalized rule (2.24 versus 1.64). The estimation of value function is more efficient by
using Int-Ben (sd = 1.27) comparing to ABLO-H (sd = 1.40), while the estimation of ITR benefit
is equally efficient for Int-Ben (sd = 1.98) and ABLO-H (sd = 1.98) with a larger estimation of
overall benefit.
Table 4.3: Overall performance of the four methods in EMBARC study using HEAL ITR
Method ABLO-L ABLO-H Int-Equal Int-Ben
Value 7.236(1.602) 7.634(1.399) 7.640(1.359) 7.712(1.266)
Benefit 1.331(2.485) 2.041(1.975) 2.042(2.179) 2.239(1.982)















































∗:Distribution of estimated ITR benefit (the higher the better) and change in HAM-D score (the larger the better)
at the end of stage 1 treatment for four methods (based on 100 cross-validation)
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Table 4.4: Overall performance of the four methods to handle blockwise feature domain data in
EMBARC study
Method ABLO-L ABLO-H Int-Equal Int-Ben
Value 7.217(1.438) 7.634(1.399) 7.672(1.351) 7.949(1.371)
Benefit 1.253(2.206) 2.041(1.975) 2.113(1.968) 2.682(2.024)











































∗:Distribution of estimated ITR benefit (the higher the better) and change in HAM-D score (the larger the better)
at the end of stage 1 treatment for four methods (based on 100 cross-validation)
Next, we present an application to handle blockwise feature domain data when learning an ITR.
In EMBARC, 104 subjects have complete clinical measures but do not have complete neuroimaging
and behavioral phenotyping measures. In the following, we will use these 104 subjects as the study
1 with low-resolution covariates to improve the performance of the high-resolution ITR learned
from the remaining 138 subjects with complete feature variables. The coarsened ITR learned
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from study 1 includes all the clinical measures at baseline, i.e., age, gender, race, baseline QIDs
score, and HAM-D score, while the high-resolution ITR includes the selected fMRI and behavioral
phenotyping measure. We repeated the same procedure as using the HEAL study for 100 times
and reported the results in Table 4.4 and Figure 4.5. The ITR benefit of Int-Ben (2.68, sd=2.02)
is larger than that using HEAL ITR (2.24, sd=1.98). The coarsened ITR learned from EMBARC
includes more feature variables and more subjects than HEAL, which lead to a greater improvement
in performance of the high-resolution ITR.
4.6 Discussion
In this work, we propose integrative learning methods to estimate integrative ITRs with combined
information across multiple trials. In practice, it is rare for RCTs to collect exactly the same feature
variables, given different hypotheses and goals. Our method does not require all the trials to collect
the same subsets of feature variables, which allows more flexibility comparing to integrative analysis
that combines multiple data sets into one data set. Although here we focused on linear decision
rules, our method can be generalized to any nonparametric form of decision rules or using other
loss functions to replace zero-one loss for optimization (4.1) and (4.2). Our integrative methods
improve the efficiency and reproducibility not only for high-resolution ITRs but also for coarsened
ITRs by using a regularized value function to incorporate information from other related studies
and a data-driven method to determine how much evidence each study contributes to the integrative
ITR.
Here a linear regression is used to estimate the benefit of ITRs estimated from other studies.
Other nonparametric or machine learning methods can be considered. In addition, future studies
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can be developed to explore other methods to properly weigh the evidence of RCTs, such as using
Composite Interaction Tree (CITree, Qiu and Wang, 2018). Another extension is to apply the
integrative learning methods to observational studies, where one difficulty is how to properly weigh
the evidence of RCTs versus observational studies when both types of studies are present. Due to
the virtue of randomization in RCTs, an unbiased estimator of expected clinical outcome given a
subset of features is also an unbiased estimator of the expected clinical outcome given comprehensive
features, which may not be true for observational studies with unknown confounders. This causes
another difficulty in applying integrative learning to observational studies. In this work, we derived
the underlying Bayesian rules for the integrative learning method, which shows that our integrative
rule maximizes a weighted combination of conditional treatment effects given differential subsets
of feature variables. An interesting theoretical work would be to show that the integrative learning
method is more efficient compared to the ITRs learned from single trials.
There are several limitations for the proposed method. First, integrative learning may not
improve performance when subjects from multiple trials follow substantially different distributions,
especially when f0 and fk yield different treatment recommendations for a large number of subjects.
However, our tuning parameters are chosen adaptively based on data to prevent integrative learning
from deteriorating performance in this setting. For example, when the target population is the first
trial, which has substantially different distribution from the second trial, we expect that the tuning
parameter λ will be chosen close to 0, and therefore the second trial does not assist in improving
the performance of the ITR. When the target population is different from all trials with observed
data, the performance gain depends on the nature of differences and we performed a few sensitivity
analyses to examine performance (see for example, Table C.1 and C.2). Another limitation of the
integrative learning is that it requires the same two treatments are assessed across multiple trials.
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It is interesting to extend the current integrative learning method to handle multiple treatments
using evidence from direct and indirect comparisons, which is similar to network meta-analysis
(Tonin et al., 2017).
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Appendix A
Appendices for Chapter 2
A.1 Computing the Theoretical Optimal Linear Rule
Here we derive the theoretical optimal linear rule f∗L in the class of all linear rules f ∈ L under our
simulation settings in Section 2.4. Let G be the latent class identifier in the simulations. Define
G|(X,W, V,A,U)=G|X as the class number, which only depends onX = (X1, X2, · · · , Xp), where
Xj |G = k ∼ N(µk, 1) for j = 1, · · · , p, and k = 1, 2, 3, 4. For a given treatment decision rule f , the




pi(A|X) {I(Af(X, V,W,U) > 0)}
]
= E [I(f(X, V,W,U) > 0) {E(R|X, V,W,U , A = 1)− E(R|X, V,W,U , A = −1)}]
+ E
{
E(R|X, V,W,U , A = −1)}.
Because E {E(R|X, V,W,U , A = −1)} is a constant which doesn’t depend on f , maximizing the
expected value function is equivalent to maximizing E {I(f(X, V,W,U) > 0)Ω(X,W )} , where
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under the simulation model for E(R|X, V,W,U , A) we can obtain
Ω(X,W ) = P (G = 1|X) {δ1 + (α11 − α21)W}+ P (G = 2|X) {δ2 + (α12 − α22)W}
+ P (G = 3|X) {−δ1 + (α13 − α23)W}+ P (G = 4|X) {−δ2 + (α14 − α24)W} .
Next, we show that V and U are independent of optimal linear decision rule f∗L. Let f
∗
L(X,W )
maximizes the value function in class L. For any fixed V and U ,
E {I[f∗L(X,W ) > 0]Ω(X,W )} ≥ E [I{f(X, V,W,U) > 0}Ω(X,W )]
= E [I{f(X, V,W,U) > 0}Ω(X,W )|V,U ] .
Therefore, take expectation of the inequality to obtain
E [E {I(f∗L(X,W ) > 0)Ω(X,W )}] ≥ E [E {I(f(X, V,W,U) > 0)Ω(X,W )|V,U}]
= E [I{f(X, V,W,U) > 0}Ω(X,W )] .




, x˜2, · · · , x˜p),
where Xs = X
1 + X2 + · · · + Xp, and x˜2, · · · , x˜p are orthogonal to Xs, the objective function
becomes
∫ ∫










2 dXsf(W )dWdx˜2 · · · dx˜s,
where




2 {δ1 + (α11 − α21)W}+ eµ2Xs−
pµ22
2 {δ2 + (α12 − α22)W}
+eµ3Xs−
pµ23
2 {−δ1 + (α13 − α23)W}+ eµ4Xs−
pµ24
2 {−δ2 + (α14 − α24)W} .
APPENDIX A. APPENDICES FOR CHAPTER 2 108
Because (x˜2, · · · , x˜p) are independent noise variables, as shown before, the optimal linear rule only
depends on Xs and W . The objective function is thus equivalent to
∫ ∫
I {f(Xs,W ) > 0}Ω(Xs,W )dXsf(W )dW.
As Xs ∼ 14N(µ1, p) + 14N(µ2, p) + 14N(µ3, p) + 14N(µ4, p) and W ∼ N(0, 1), where µk is the mean
of Xp in the kth class. Monte Carlo method can be applied to find the optimal linear rule f∗L.
A.2 Additional Simulation Results
We performed additional simulations to vary the strength of the informative feature variable W ,
such that its effects in different settings are α =
 1 1 0.3 0.6
0.5 0.5 0.3 0.6
.
Results from 500 replicates are summarizied in Table A.1, Figure A.1, and A.2. ABLO with
linear kernel has the highest optimal treatment classification accuracy regardless of the sample
size for both settings, and also estimates the ITR benefit closest to the true global maximal value
of 0.705 on the overall sample. PM, Q-learning, and O-learning underestimate the ITR benefit,
especially when the sample size is smaller (N = 400 training, 400 testing). Thus they do not achieve
the maximal value of the theoretical optimal linear rule. The performance of estimating subgroup
ITR benefit is similar to the overall sample. ABLO outperforms other methods with subgroup ITR
benefit closer to the true global maximal value (e.g., in groups W ∈ [−0.5, 0.5] and W > 0.5).
A.3 Sensitivity to the Starting Values of ABLO
To evaluate the sensitivity of the algorithm to starting values, we include the algorithm convergence
path of two example datasets in terms of value function and weighted ramp loss function. In Figure
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A.3, lines indicate convergence paths given different initial values. In the first example dataset, the
algorithm converges to the same value function and ramp loss. However, the algorithm converges
fastest if starting with O-leaning estimates. In the second dataset, the algorithm is more sensitive
to different starting values, but the one starting with O-learning estimates performs the best, which
is also the proposed starting values for ABLO.
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*: Dotted-dashed lines represent the benefit (top panels) and accuracy (bottom panels under the theoretical global
optimal treatment f∗. Dashed lines represent the benefit and accuracy under the theoretical optimal linear rule f∗L.
The methods being compared are (from left to right): PM: predictive modeling by random forest; Q-learning:
Q-learning with linear regression; O-learning: improved single stage O-learning (Liu et al., 2014); ABLO:
asymptotically best linear O-learning. This figure appears in color in the electronic version of this article.
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Setting 2 (N = 1600)
*:Black dotted-dashed lines represent the benefit under the theoretical global optimal treatment f∗. Red dashed
lines represent the benefit under the theoretical optimal linear rule f∗L. The methods being compared are (from left
to right): PM: predictive modeling by random forest; Q-learning: Q-learning with linear regression; O-learning:
improved single stage O-learning (Liu et al., 2014); ABLO: asymptotically best linear O-learning. This figure
appears in color in the electronic version of this article.
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Figure A.3: Performance of the algorithm on two example datasets evaluated by value function
and penalized weighted sum of ramp loss
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*: Initial 1 starts β from the estimates obtained by O-learning; Initial 2 starts from β = 0; Initial 3 starts from
β = (1, · · · , 1,−1, · · · ,−1)T , where half of the components are 1 and the other half are −1; Initial 4 starts from
β = (1, 0, · · · , 0)T . This figure appears in color in the electronic version of this article.
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Appendix B
Appendices for Chapter 3
B.1 Estimation of Variance for δ̂C1(f̂)− δ̂C2(f̂)
In a binary tree, consider a binary partition (e.g., based on X1 > c or X1 ≤ c) to partition n
subjects with feature variables Xi into two subgroups C1 and C2. Recall that in an honest CITree,
f̂ denotes the ITR estimated from an independent training sample and the estimated subgroup





Xi ∈ C1, Ai = sign(f̂(Xi))
}
Ri/pii∑n





Xi ∈ C1, Ai 6= sign(f̂(Xi))
}
Ri/pii∑n
i=1 I((Xi ∈ C1)
,
where pii = pi(Ai|Xi).
To apply HTB test for C1 and C2, it is necessary to estimate the variance of δ̂C1(f̂) − δ̂C2(f̂),




















































Define δ̂C1(f̂) = φ(Fn,Gn) = FnGn , and Pn = (Fn,Gn). By functional delta method of Van der Vaart
(2000), we have
√
n {φ(Pn)− φ(P )} ≈ φ′P
{√












































































can be estimated by em-
pirical mean, variance and covariance.



























































































































Cov {g(X), g∗(X)} .
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Appendix C
Appendices for Chapter 4
C.1 Simulation Study for Multiple Trials with Different Treat-
ment Effects
In this setting, the simulation models are slightly different across trials with different treatment
effect sizes. The clinical outcome R for all the trials is generated by
R = φ(X) ∗A+ 0.5 ∗X1 + ,  ∼ N(0, 0.25)
φ(X) = X1 − 0.5X2 − αX3 − βX4 + 0.3(X25 > 0.64)− 0.3(X6 > 0). (C.1)
In the study with comprehensive feature variables (study 0), X1, · · · , X5 are observed, only X6 is
an unobserved latent variable. The interaction effect of X3 and X4 are both α = β = 0.8. However,
in the study with low-resolution variables (study 1), only X1, X2 and X3 were collected in the trial
and can be used to estimate a coarsened ITR. The interaction effect of X3 and X4 were set to 0.1,
meaning that both X1 and X4 don’t contribute much to the selection of optimal treatment. All
the feature variables X1, · · · , X6, observed or unobserved, were generated independently and follow
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standard normal distribution. Treatment A was randomly assigned from {−1, 1} for each subject
with equal probability.
In the validation data set, we are trying to simulate a more general population with treatment
interaction effect between the data collected from study 0 and study 1. For validation setting 1 to
4, we set α = β as 0.3, 0.4, 0.5, and 0.6. Similar to Section 4.4.2, we applied integrative learning
for high-resolution ITR (study 0) using coarsened ITR learned from study 1 and validated it on
validation setting 1 to 4. Results from 100 repetitions are shown in Table C.1 and Figure C.1. In
validation setting 1, ABLO-L performs better than ABLO-H with larger benefit and accuracy. It is
also more efficient compared to all other methods with a smaller standard deviation in estimating
benefit and value function. This is because the interaction effect of X3 and X4 is 0.3, which is
relatively small and closer to the sample collected from study 1. Also, the coarsened ITR is simpler
than high-resolution ITR and with fewer model assumptions, and therefore making the model less
variable in estimating the benefit and value function. However, when the treatment effect gets
larger in setting 2 to 4, Int-Ben always performs the best with the largest benefit and accuracy,
also with the smallest standard deviation of benefit.
Next, we apply integrative learning for low-resolution ITR (study 1) using high-resolution ITR
learned from study 0 and validated it on validation setting 1 to 4. Results are shown in Table C.2
and Figure C.2. In all validation settings, Int-Ben performs best in terms of a larger estimated
benefit and smaller standard deviation by borrowing information from high-resolution ITR learned
from study 0. Overall, the estimation of benefit became less efficient for all methods as the treatment
effect increases since the validation data became more and more different to the study where low-
resolution ITR was estimated.
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Table C.1: Mean and standard deviation of overall benefit, value and accuracy rates for integrative
learning of high-resolution ITR comparing to ITRs by ABLO on single studies
ABLO-H ABLO-L Int-Equal Int-Ben
Benefit Setting 1 1.757(0.057) 1.824(0.028) 1.849(0.063) 1.868(0.047)
Setting 2 1.874(0.044) 1.816(0.037) 1.935(0.041) 1.951(0.029)
Setting 3 2.014(0.032) 1.779(0.053) 2.042(0.028) 2.056(0.019)
Setting 4 2.190(0.029) 1.821(0.059) 2.195(0.044) 2.209(0.027)
Value Setting 1 0.887(0.027) 0.913(0.014) 0.932(0.030) 0.941(0.022)
Setting 2 0.938(0.022) 0.901(0.019) 0.967(0.020) 0.975(0.014)
Setting 3 1.015(0.018) 0.901(0.027) 1.031(0.014) 1.038(0.010)
Setting 4 1.089(0.016) 0.905(0.029) 1.092(0.023) 1.098(0.014)
Accuracy Setting 1 0.852(0.020) 0.880(0.012) 0.890(0.029) 0.898(0.022)
Setting 2 0.875(0.018) 0.848(0.013) 0.904(0.020) 0.913(0.017)
Setting 3 0.903(0.017) 0.820(0.015) 0.919(0.016) 0.928(0.012)
Setting 4 0.921(0.014) 0.797(0.013) 0.923(0.021) 0.930(0.015)
∗: ABLO-H is estimated by ABLO using high-resolution data only;
ABLO-L is estimated by ABLO using low-resolution data only;
Int-Equal is estimated by integrative learning for high-resolution ITR with equal weights for all subjects;
Int-Ben is estimated by integrative learning for high-resolution ITR weighted by estimated benefit.














































































∗: ABLO-H is estimated by ABLO using high-resolution data only;
ABLO-L is estimated by ABLO using low-resolution data only;
Int-Equal is estimated by integrative learning for high-resolution ITR with equal weights for all subjects;
Int-Ben is estimated by integrative learning for high-resolution ITR weighted by estimated benefit.
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Table C.2: Mean and standard deviation of overall benefit, value and accuracy rates for integrative
learning of low-resolution ITR comparing to ITRs by ABLO on single studies
ABLO-L Int-Equal Int-Ben
Benefit Setting 1 1.794(0.029) 1.816(0.020) 1.821(0.018)
Setting 2 1.853(0.041) 1.895(0.029) 1.911(0.021)
Setting 3 1.844(0.051) 1.903(0.042) 1.927(0.032)
Setting 4 1.844(0.065) 1.922(0.056) 1.956(0.043)
Value Setting 1 0.876(0.017) 0.890(0.011) 0.895(0.009)
Setting 2 0.929(0.021) 0.950(0.014) 0.958(0.010)
Setting 3 0.955(0.025) 0.983(0.021) 0.995(0.016)
Setting 4 0.919(0.032) 0.958(0.028) 0.976(0.022)
Accuracy Setting 1 0.881(0.012) 0.890(0.009) 0.891(0.008)
Setting 2 0.857(0.014) 0.871(0.010) 0.876(0.008)
Setting 3 0.825(0.013) 0.840(0.011) 0.847(0.009)
Setting 4 0.806(0.015) 0.826(0.015) 0.835(0.012)
∗: ABLO-L is estimated by ABLO using low-resolution data only;
Int-Equal is estimated by integrative learning for low-resolution ITR with equal weights for all subjects;
Int-Ben is estimated by integrative learning for low-resolution ITR weighted by estimated benefit.




























































*: ABLO-L is estimated by ABLO using low-resolution data only;
Int-Equal is estimated by integrative learning for low-resolution ITR with equal weights for all subjects;
Int-Ben is estimated by integrative learning for low-resolution ITR weighted by estimated benefit.
